telavancin profile

telavancin: an anti-infective agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3081362
CHEMBL ID	507870
CHEBI ID	71229
SCHEMBL ID	8287015
MeSH ID	M0468816

Synonym
hsdb 8194
unii-xk134822z0
vancomycin, n3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
telavancin [inn]
xk134822z0 ,
td-6424
telavancin
td6424
CHEMBL507870
vancomycin, n(sup 3'')-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
televancin [vandf]
telavancin [vandf]
telavancin [mart.]
telavancin [who-dd]
telavancin [mi]
televancin
n(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin
telavancine
CHEBI:71229 ,
telavancinum
telavancina
DB06402
telavancin, antibiotic for culture media use only
T-1455
SCHEMBL8287015
AC-30598
DTXSID10873383 ,
Q7695658
gtpl10925
CS-0069761
HY-112959
n(3'')-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)vancomycin
j01xa03
dtxcid80820900
telavancin (mart.)
(1s,2r,18r,19r,22s,25r,28r,40s)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-(((2s,3r,4s,5s,6r)-3-(((2s,4s,5s,6s)-4-((2-(decylamino)ethyl)amino)-5-hydroxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-2

Excerpt	Reference	Relevance
"Telavancin is a novel bactericidal lipoglycopeptide with multiple mechanisms of action against gram-positive pathogens. "	( Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Cars, O; Löwdin, E; Odenholt, I, 2007)	2.08
"Telavancin is an investigational bactericidal lipoglycopeptide with a multifunctional mechanism of action, as demonstrated against methicillin-resistant Staphylococcus aureus. "	( Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Barriere, S; Drusano, GL; Gotfried, M; Lodise, TP, 2008)	3.23
"Telavancin is an investigational, rapidly bactericidal lipoglycopeptide antibiotic that is being developed to treat serious infections caused by gram-positive bacteria. "	( Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Benton, BM; Draghi, DC; Krause, KM; Pillar, C; Sahm, DF; Thornsberry, C, 2008)	2.07
"Telavancin is an investigational lipoglycopeptide antibiotic that is active against gram-positive pathogens. "	( Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Darouiche, RO; Mansouri, MD; Schneidkraut, MJ, 2009)	2.1
"Telavancin is an investigational lipoglycopeptide antibiotic currently being developed for the treatment of serious infections caused by gram-positive bacteria. "	( Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Benton, BM; Hartouni, SR; Humphrey, PP; Janc, JW; Lunde, CS; Mammen, M, 2009)	3.24
"Telavancin is a bactericidal, semisynthetic lipoglycopeptide indicated in the United States for the treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria and is under investigation as a once-daily treatment for nosocomial pneumonia. "	( Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Benton, BM; Blais, J; Hill, CM; Humphrey, PP; Janc, JW; Kinana, A; Krause, KM; Lewis, SR; Mammen, M, 2010)	2.02
"Telavancin is a lipoglycopeptide antibiotic with limited pharmacokinetic data to guide drug dosing in patients receiving haemodialysis."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	3.51
"Telavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens including Staphylococcus aureus, the most frequent cause of osteomyelitis. "	( Outpatient treatment of osteomyelitis with telavancin. Adams, JS; Dretler, RH; Krinsky, AH; Luu, Q; Prokesch, RC; Schroeder, CP; Van Anglen, LJ, 2017)	2.16
"Telavancin is a reliable alternative to vancomycin in the treatment of MRSA-confirmed infections despite the incidence of serious adverse events. "	( A comparison of telavancin and vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections: A meta-analysis. Liu, Y; Wang, J, 2017)	2.24
"Telavancin is a lipoglycopeptide semi-synthetic derivative of vancomycin used for select infections caused by Gram-positive bacteria including "	( Telavancin-associated acute kidney injury . Cavanaugh, C; Moeckel, GW; Perazella, MA, 2019)	3.4
"Telavancin is a novel semisynthetic lipoglycopeptide derivative of vancomycin with a dual mode of action. "	( Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant. Benton, BM; Lunde, CS; Song, Y; Wilkinson, BJ, 2013)	2.13
"Telavancin is a once-daily injectable, semisynthetic lipoglycopeptide antimicrobial with bactericidal activity against susceptible Gram-positive pathogens, including MRSA."	( The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Barriere, SL, 2014)	1.39
"Telavancin is a dual action, bactericidal lipoglycopeptide. "	( In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. Coyle, E; Nesher, L; Prince, RA; Rolston, K; Shelburne, S; Wang, W, 2014)	2.16
"Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S."	( A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. Barriere, SL; Corey, GR; Fowler, VG; Kitt, MM; Lentnek, A; Miró, JM; O'Riordan, W; Pullman, J; Stryjewski, ME; Tambyah, PA, 2014)	1.41
"Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against Gram-positive pathogens. "	( Variability in telavancin cross-reactivity among vancomycin immunoassays. Barriere, SL; Clark, D; Liao, S; McConeghy, KW; Rodvold, KA; Worboys, P, 2014)	2.2
"Telavancin is a parenteral lipoglycopeptide antibiotic with a dual mechanism of action contributing to bactericidal activity against multidrug-resistant Gram-positive pathogens. "	( Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection. Hegde, SS; Janc, JW, 2014)	2.22
"Telavancin is a bactericidal lipoglycopeptide antibiotic that is active against a range of clinically relevant gram-positive pathogens including MRSA."	( Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Barriere, SL; Bassetti, M; Corey, GR; Rubinstein, E; Stryjewski, ME, 2015)	1.47
"Telavancin is a lipoglycopeptide antibiotic with activity against MRSA."	( Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis. Peaper, DR; Ruggero, MA; Topal, JE, 2015)	2.58
"Telavancin is a semisynthetic lipoglycopeptide derivative of vancomycin. "	( Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Karlowsky, JA; Nichol, K; Zhanel, GG, 2015)	3.3
"Telavancin is a lipoglycopeptide antibiotic with potent in vitro activity against a range of gram-positive pathogens, including MRSA, methicillin-susceptible S."	( The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia. Sandrock, CE; Shorr, AF, 2015)	1.52
"Telavancin is a lipoglycopeptide with potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. "	( In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Kuti, JL; Nicolau, DP; Thabit, AK, 2016)	2.12
"Telavancin is a novel lipoglycopeptide derivative of vancomycin that has activity against Gram-positive aerobic and anerobic bacteria, for the treatment of serious infections, including complicated skin and skin structure infections (cSSSI) and pneumonia."	( Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia. Adamantia, L; Antoni, T, 2016)	2.12
"Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gram-positive aerobic bacteria, and is especially effective against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria resistant to VAN. "	( Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience. Dimakou, K; Liapikou, A; Toumbis, M, 2016)	3.32
"Telavancin is a novel anti-MRSA agent that both inhibits bacterial cell wall synthesis and disrupts membranes by depolarization."	( Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains. Abdelhady, W; Bayer, AS; Tang, C'; Xiong, YQ, 2016)	1.46
"Telavancin is a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, including concentration-dependent inhibition of bacterial cell wall synthesis and disruption of the functional integrity of the cell membrane."	( A new lipoglycopeptide: telavancin. Nannini, EC; Stryjewski, ME, 2008)	1.37
"Telavancin is a lipoglycopeptide administered intravenously once-daily and excreted with urine. "	( The role of telavancin in the treatment of MRSA infections in hospital. Bassetti, M; Mikulska, M; Nicolini, L; Righi, E; Viscoli, C, 2009)	2.17
"Telavancin is a lipoglycopeptide derivative of vancomycin. "	( Telavancin: a new lipoglycopeptide for gram-positive infections. Drew, RH; Smith, WJ, 2009)	3.24
"Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States. "	( Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Barriere, SL; Churchwell, MD; Grio, M; Mueller, B; Patel, JH; Seroogy, JD, 2009)	3.24
"Telavancin is a bactericidal lipoglycopeptide active in vitro against Gram-positive pathogens including hVISA and vancomycin-intermediate S."	( Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. Benton, BM; Blais, J; Hegde, SS; Krause, KM; Lewis, SR; Skinner, R, 2010)	1.46
"Telavancin is an intravenous lipoglycopeptide antibiotic active against many Gram-positive pathogens via inhibition of bacterial cell wall synthesis and disruption of bacterial membrane function. "	( An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic. Jaw-Tsai, S; Shaw, JP, 2011)	2.06
"Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. "	( ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Barriere, SL, 2010)	2.08
"Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens."	( Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Barriere, SL; Corey, GR; Fagon, JY; Friedland, HD; Genter, FC; Kanafani, ZA; Kitt, MM; Kollef, MH; Lalani, T; Lee, PC; Lentnek, AL; Luna, CM; Nannini, EC; Niederman, MS; Rahav, G; Rocha, MG; Rubinstein, E; Shorr, AF; Stryjewski, ME; Torres, A, 2011)	3.25
"Telavancin is a new lipoglycopeptide antibiotic for the treatment of Gram-positive infections. "	( Effect of telavancin on human intestinal microflora. Nord, CE; Rashid, MU; Weintraub, A, 2011)	2.21
"Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens."	( Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Corey, GR; Kanafani, ZA; Rubinstein, E; Stryjewski, ME, 2011)	3.25
"Telavancin is a lipoglycopeptide with a dual mechanism of action, as it inhibits peptidoglycan polymerization/cross-linking and disrupts the membrane potential."	( Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Rybak, MJ; Steed, ME; Vidaillac, C, 2012)	1.46
"Telavancin is a novel semisynthetic lipoglycopeptide derivative of vancomycin with a decylaminoethyl side chain that is active against Gram-positive bacteria, including Staphylococcus aureus strains resistant to methicillin or vancomycin. "	( Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Benton, BM; Lunde, CS; Song, Y; Wilkinson, BJ, 2012)	2.06
"Telavancin (TLV) is a lipoglycopeptide agent with a dual mechanism of activity (cell wall synthesis inhibition plus depolarization of the bacterial cell membrane)."	( Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Bayer, AS; Chen, L; Hady, WA; Kreiswirth, BN; Xiong, YQ; Yang, SJ, 2012)	2.54
"Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens."	( Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. Falagas, ME; Makris, MC; Mavros, MN; Polyzos, KA; Rafailidis, PI; Vardakas, KZ, 2012)	1.41
"Telavancin is a novel, rapidly cidal, dual-action glycopeptide. "	( In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. Adkin, R; Chaudhry, A; Hope, R; Livermore, DM, 2013)	2.15
"Telavancin is a new semisynthetic glycopeptide anti-infective with multiple mechanisms of action, including inhibition of bacterial membrane phospholipid synthesis and inhibition of bacterial cell wall synthesis. "	( In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA, 2004)	2.01
"Telavancin is a rapidly bactericidal antibiotic with multiple mechanisms of action against gram-positive bacteria. "	( Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. Barriere, S; Genter, F; Hoelscher, D; Kitt, M; Morganroth, J; Spencer, E, 2004)	2.05
"Telavancin (TD-6424) is a novel lipoglycopeptide that produces rapid and concentration-dependent killing of clinically relevant gram-positive organisms in vitro. "	( Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Hegde, SS; Judice, JK; Kaniga, K; McCullough, J; Obedencio, G; Pace, J; Reyes, N; Shaw, JP; Skinner, R; Thomas, R; Vanasse, N; Wiens, T, 2004)	2.09
"Telavancin is a novel lipoglycopeptide antibiotic that possesses rapid in vitro bactericidal activity against a broad spectrum of clinically relevant gram-positive pathogens."	( Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Benton, BM; Cass, RT; Chang, R; Debabov, DV; Gao, Q; Higgins, DL; Hubbard, JM; Humphrey, PP; Kaniga, K; Karr, DE; Krause, KM; Leung, J; Sandvik, E; Schmidt, DE; Wu, T, 2005)	2.49
"Telavancin is a bactericidal lipoglycopeptide with a multifunctional mechanism of action. "	( Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Barriere, SL; Chu, VH; Corey, GR; Dunbar, LM; Fowler, VG; Kitt, MM; Morganroth, J; O'Riordan, WD; Stryjewski, ME; Vallée, M; Warren, BL; Young, DM, 2006)	3.22
"Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action that involves the inhibition of cell-wall synthesis and disruption of bacterial cell-membrane barrier functions."	( Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Kanafani, ZA, 2006)	2.5
"Telavancin is a lipoglycopeptide antimicrobial agent under development for use in the treatment of multidrug-resistant gram-positive infections. "	( Telavancin: a novel lipoglycopeptide antimicrobial agent. Attwood, RJ; LaPlante, KL, 2007)	3.23
"Telavancin is a promising new agent for gram-positive infections and may offer an alternative to vancomycin for MRSA-associated infections."	( Telavancin: a novel lipoglycopeptide antimicrobial agent. Attwood, RJ; LaPlante, KL, 2007)	3.23
"Telavancin is a once-daily lipoglycopeptide antibiotic structurally derived from vancomycin. "	( Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Leonard, SN; Rybak, MJ, 2008)	3.23
"Telavancin is a lipoglycopeptide with multiple mechanisms of action that include membrane-destabilizing effects towards bacterial cells. "	( Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). Barcia-Macay, M; Mingeot-Leclercq, MP; Mouaden, F; Tulkens, PM; Van Bambeke, F, 2008)	2.08
"Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. "	( In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. Benton, BM; Draghi, DC; Krause, KM; Pillar, C; Sahm, DF; Thornsberry, C, 2008)	2.11
"Telavancin is an investigational, rapidly bactericidal lipoglycopeptide with a multifunctional mechanism of action."	( Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Barriere, SL; Corey, GR; Fowler, VG; Friedland, HD; Graham, DR; Hopkins, A; Kitt, MM; Lentnek, A; O'Riordan, W; Ross, DP; Stryjewski, ME; Wilson, SE; Young, D, 2008)	3.23

Excerpt	Reference	Relevance
"Telavancin has a dual mechanism of antibacterial action, disrupting peptidoglycan synthesis and cell membrane function."	( Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Karlowsky, JA; Nichol, K; Zhanel, GG, 2015)	2.58
"Telavancin has a < 5-msec mean effect on cardiac repolarization, with a flat-dose response over a two-fold exposure range."	( Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. Barriere, S; Genter, F; Hoelscher, D; Kitt, M; Morganroth, J; Spencer, E, 2004)	1.33
"Telavancin has a prolonged postantibiotic effect and distributes well into cutaneous and pulmonary tissues."	( Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Kanafani, ZA, 2006)	2.5
"Telavancin has been shown to prolong plasmatic prothrombin (PT) and activated partial thromboplastin (aPTT) clotting times in clinical diagnostic lab-based assays."	( Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. Barriere, SL; Chin, KH; Ero, MP; Harbert, JL; Harvey, NR; Janc, JW, 2014)	1.53
"Telavancin has been demonstrated to be efficacious in multiple animal models of soft tissue, cardiac, systemic, lung, bone, brain and device-associated infections involving clinically relevant Gram-positive pathogens, including methicillin-resistant S."	( Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection. Hegde, SS; Janc, JW, 2014)	1.5
"Telavancin has potent in vitro activity against isolates of Gram-positive pathogens, including MRSA and glycopeptide-intermediate S."	( The clinical positioning of telavancin in Europe. Cornaglia, G; Courvalin, P; Lode, HM; Masterton, R; Rello, J; Torres, A, 2015)	1.43
"Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus."	( A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections. Chan, C; Hardin, TC; Smart, JI, 2015)	1.52
"Telavancin has a dual mechanism of antibacterial action, disrupting peptidoglycan synthesis and cell membrane function."	( Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Karlowsky, JA; Nichol, K; Zhanel, GG, 2015)	2.58
"Telavancin has not been tested in nosocomial pneumonia resistant to first-line antibiotics."	( Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic. , 2015)	2.58
"Telavancin has the potential to become an important therapeutic option to treat serious infections produced by resistant Gram-positive cocci, particularly those caused by methicillin-resistant S."	( A new lipoglycopeptide: telavancin. Nannini, EC; Stryjewski, ME, 2008)	1.37
"Telavancin has comparable efficacy to vancomycin and linezolid in a rabbit model of MRSA osteomyelitis."	( Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. Calhoun, JH; Thomas, TS; Wirtz, ED; Yin, LY, 2009)	2.17
"Telavancin has rapid bactericidal activity against gram-positive aerobic and anaerobic bacteria through multiple mechanisms of action. "	( Telavancin: a novel lipoglycopeptide antibiotic. Charneski, L; Patel, PN; Sym, D, 2009)	3.24
"Telavancin has the potential to prolong both PT and aPTT in vitro. "	( Effects of telavancin on coagulation test results. Adcock, DM; Barriere, SL; Goldberg, MR; Higgins, DL; Janc, JW; Macy, PA, 2011)	2.2
"Telavancin has a < 5-msec mean effect on cardiac repolarization, with a flat-dose response over a two-fold exposure range."	( Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. Barriere, S; Genter, F; Hoelscher, D; Kitt, M; Morganroth, J; Spencer, E, 2004)	1.33
"Telavancin has a prolonged postantibiotic effect and distributes well into cutaneous and pulmonary tissues."	( Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Kanafani, ZA, 2006)	2.5
"Telavancin has concentration-dependent bactericidal activity and is active against gram-positive aerobic and anaerobic organisms."	( Telavancin: a novel lipoglycopeptide antimicrobial agent. Attwood, RJ; LaPlante, KL, 2007)	2.5
"Telavancin has potent in vitro activity against contemporary Gram-positive clinical isolates from diverse geographic areas in Europe and Israel."	( In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. Benton, BM; Draghi, DC; Krause, KM; Pillar, C; Sahm, DF; Thornsberry, C, 2008)	2.11

Excerpt	Reference	Relevance
"Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin. "	( Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Crandon, JL; Kuti, JL; Nicolau, DP, 2010)	2.05
"Telavancin displays greater activity against Clostridium spp."	( New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Adam, H; Calic, D; Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Rubinstein, E; Schweizer, F; Zelenitsky, S; Zhanel, GG, 2010)	1.31
"Telavancin displays a dual mode of action and a rapid bactericidal killing."	( Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Kuti, JL; Laohavaleeson, S; Nicolau, DP, 2007)	2.5

Excerpt	Reference	Relevance
"(Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia (ASSURE); NCT00062647)."	( A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. Barriere, SL; Corey, GR; Fowler, VG; Kitt, MM; Lentnek, A; Miró, JM; O'Riordan, W; Pullman, J; Stryjewski, ME; Tambyah, PA, 2014)	1.31
"The telavancin treatment groups were not significantly different from each other."	( Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. Barriere, S; Genter, F; Hoelscher, D; Kitt, M; Morganroth, J; Spencer, E, 2004)	1.09
"Treatment with telavancin was associated with lower spleen bacterial titres, lower rates of bacteraemia and lower overall mortality than treatment with vancomycin."	( Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. Benton, BM; Blais, J; Hegde, SS; Krause, KM; Lewis, SR; Skinner, R, 2010)	1.08
"Treatment with telavancin achieved higher cure rates in patients with monomicrobial S."	( Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Barriere, SL; Corey, GR; Fagon, JY; Friedland, HD; Genter, FC; Kanafani, ZA; Kitt, MM; Kollef, MH; Lalani, T; Lee, PC; Lentnek, AL; Luna, CM; Nannini, EC; Niederman, MS; Rahav, G; Rocha, MG; Rubinstein, E; Shorr, AF; Stryjewski, ME; Torres, A, 2011)	2.15

Excerpt	Reference	Relevance
" Most adverse events were mild in severity."	( Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Barriere, S; Higgins, DL; Kaniga, K; Kitt, M; Seroogy, J; Shaw, JP, 2005)	0.56
" The most common telavancin treatment-emergent adverse events were taste disturbance, nausea, vomiting and foamy urine."	( ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Barriere, SL, 2010)	0.97
"57]), serious adverse events (OR=1."	( Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. Falagas, ME; Makris, MC; Mavros, MN; Polyzos, KA; Rafailidis, PI; Vardakas, KZ, 2012)	0.69

Excerpt	Reference	Relevance
" Plasma and ELF pharmacokinetic data were obtained from 20 healthy volunteers, and the pharmacokinetic samples were assayed by a validated liquid chromatography-tandem mass spectrometry technique."	( Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Barriere, S; Drusano, GL; Gotfried, M; Lodise, TP, 2008)	1.79
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"The aim of this study was to assess the steady-state pharmacokinetic parameters of telavancin, an investigational bactericidal lipoglycopeptide, after intravenous (iv) administration to healthy male and female subjects."	( Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. Barriere, SL; Goldberg, MR; Kitt, MM; Wong, SL, 2008)	0.83
" Blood and urine samples were collected for pharmacokinetic analyses at admission, on day 3 pre-infusion and up to 48 h after the start of the day 3 infusion for 73 subjects (45 males and 28 females)."	( Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. Barriere, SL; Goldberg, MR; Kitt, MM; Wong, SL, 2008)	0.6
" No gender-related differences in the pharmacokinetic disposition of telavancin were observed."	( Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. Barriere, SL; Goldberg, MR; Kitt, MM; Wong, SL, 2008)	0.84
"This randomized crossover study in healthy participants assessed pharmacokinetic interactions between telavancin, aztreonam, and piperacillin/tazobactam."	( Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. Barriere, SL; Goldberg, MR; Kinzig, M; Kitt, MM; Sörgel, F; Wong, SL, 2009)	0.79
" Pharmacokinetic studies conducted in patients receiving CRRT and telavancin are needed to confirm these in vitro findings."	( Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Barriere, SL; Churchwell, MD; Grio, M; Mueller, B; Patel, JH; Seroogy, JD, 2009)	2.03
"Plasma samples were collected for pharmacokinetic analysis before the infusion and 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours after the start of the infusion."	( Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.59
"No apparent differences were observed in the pharmacokinetic disposition of telavancin in patients with hepatic impairment compared with healthy controls in this pilot study."	( Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.82
"These pharmacokinetic data show that intravenous telavancin administered at the intended therapeutic dose does not affect the pharmacokinetics of intravenous midazolam."	( Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Ballow, CH; Barriere, SL; Goldberg, MR; Kitt, MM; Wong, SL, 2010)	1.02
"To assess the safety and tolerability, and the effect of sex on the pharmacokinetic disposition, of a single intravenous dose of telavancin 10 mg/kg in elderly (> or = 65 yrs) subjects."	( Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.82
"For the pharmacokinetic analysis, blood samples were collected before drug administration and at regular intervals up to 48 hours after the start of the infusion."	( Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.62
"The pharmacokinetic parameters of telavancin were similar between elderly men and women and comparable to historical results in healthy young subjects."	( Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.89
" Non-compartmental pharmacokinetic parameters of telavancin (clearance [Cl], steady-state volume of distribution [Vss], area under the concentration curve [AUC], and elimination half-life [t(1/2)]) were determined for five preclinical species (mice, rats, rabbits, dogs, and monkeys)."	( An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic. Jaw-Tsai, S; Shaw, JP, 2011)	0.87
" faecium [VREF] strain) were compared using an in vitro pharmacokinetic model of infection."	( Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Bowker, KE; Elliott, HC; MacGowan, AP; Noel, AR; Tomaselli, S, 2011)	0.69
"A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify sources of interindividual variability."	( Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Barriere, SL; Samara, E; Shaw, JP; Wong, SL; Worboys, P, 2012)	0.94
" Pharmacokinetic analysis of telavancin and hydroxypropylbetadex plasma concentration versus time was performed in these subjects."	( Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Barriere, SL; Wong, SL; Worboys, PD, 2015)	0.99
" The activity of telavancin against MRSA and MSSA after prior vancomycin exposure was studied in an in vitro pharmacodynamic model."	( In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Kuti, JL; Nicolau, DP; Thabit, AK, 2016)	1.02
" In our review, particular attention was paid to those articles that reviewed the pharmacokinetic characteristics of the drug and animal models of infection."	( Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia. Adamantia, L; Antoni, T, 2016)	0.68
" Our aim was to develop a physiologically based pharmacokinetic (PBPK) model of telavancin to design optimized dosing regimens for obese patients with hospital-acquired pneumonia (HAP) and varying renal function."	( Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Ke, M; Lin, C; Wu, W; Ye, L, 2021)	1.07
"The PBPK model was verified using clinical pharmacokinetic (PK) data of telavancin in healthy populations with varying renal function and obese populations with normal renal function."	( Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Ke, M; Lin, C; Wu, W; Ye, L, 2021)	1.07
"Telavancin is a lipoglycopeptide antibiotic with limited pharmacokinetic data to guide drug dosing in patients receiving haemodialysis."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	3.51
"This was a Phase IV, prospective, open-label, single-centre, crossover pharmacokinetic study (ClinicalTrials."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	2.06

Excerpt	Reference	Relevance
" Here we assessed the in vitro activity of the novel lipoglycopeptide telavancin (TLV) when combined with colistin (COL) versus 13 Gram-negative type strains and 66 clinical isolates."	( In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Hornsey, M; Longshaw, C; Phee, L; Wareham, DW, 2012)	0.93
" Due to structural and mechanistic similarities between vancomycin and telavancin, we investigated the activity of telavancin combined with nafcillin and imipenem compared to the known synergistic combination of telavancin and gentamicin."	( Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Gandhi, RG; Leonard, SN; Patel, MD; Supple, ME, 2013)	0.92

Excerpt	Relevance	Reference
" The findings of these studies collectively suggest that once-daily dosing of telavancin may provide an effective approach for the treatment of clinically relevant infections with gram-positive organisms."	( Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Hegde, SS; Judice, JK; Kaniga, K; McCullough, J; Obedencio, G; Pace, J; Reyes, N; Shaw, JP; Skinner, R; Thomas, R; Vanasse, N; Wiens, T, 2004)	0.88
"Telavancin, a once-daily dosing lipoglycopeptide derived from vancomycin, has a broad-spectrum microbiologic activity against gram-positive bacteria, including vancomycin-resistant staphylococci."	( Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Kuti, JL; Laohavaleeson, S; Nicolau, DP, 2007)	3.23
" Over the entire dosing interval, telavancin was present in ELF and AMs at concentrations up to 8-fold and 85-fold, respectively, above its MIC 90 for methicillin-resistant Staphylococcus aureus (0."	( Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Barriere, SL; Benton, BM; Goldberg, MR; Gotfried, MH; Kitt, MM; Krause, KM; Shaw, JP, 2008)	0.89
" Telavancin is eliminated renally, and a dosage reduction is required in renally impaired patients."	( Telavancin: a novel lipoglycopeptide antimicrobial agent. Attwood, RJ; LaPlante, KL, 2007)	2.69
" The extended PAE of telavancin, together with its long elimination half-life in humans, supports once-daily dosing for this investigational drug."	( Postantibiotic effects of telavancin against 16 gram-positive organisms. Appelbaum, PC; Pankuch, GA, 2009)	0.97
" The need for dosage adjustments based on age, gender and obesity appear unnecessary."	( Telavancin: a new lipoglycopeptide for gram-positive infections. Drew, RH; Smith, WJ, 2009)	1.8
" Telavancin is excreted by the kidneys, and thus, dosage adjustments are required in cases of renal failure."	( Telavancin: a novel lipoglycopeptide. Johnson, LB; Saravolatz, LD; Stein, GE, 2009)	2.71
" Thus, adjustment of the standard telavancin dosage regimen does not appear to be required in patients with mild-to-moderate hepatic impairment."	( Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.87
" No evidence was found to support telavancin dosage adjustment based on age or sex."	( Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Barriere, SL; Goldberg, MR; Kitt, MM; Shaw, JP; Wong, SL, 2010)	0.89
" The use of higher doses and less-frequent dosing of existing agents is being explored, and exciting new developments include the emergence of agents with broader-spectrum activity against drug-resistant organisms and the use of antifungal agents in the OPAT setting."	( Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. Chapman, AL; Lessing, MP; Sanderson, F; Seaton, RA; Török, ME, 2010)	0.36
" These analyses support current dosing recommendations for telavancin based on patient weight and renal function."	( Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Barriere, SL; Samara, E; Shaw, JP; Wong, SL; Worboys, P, 2012)	0.91
" When a clinically relevant exposure of telavancin was given daily to rats, some differences in kidney injury were attributed to the dosing regimen."	( Kidney injury associated with telavancin dosing regimen in an animal model. Bowers, DR; Ledesma, KR; Tam, VH; Truong, LD; Zhou, J, 2015)	0.97
" Pharmacokinetic and pharmacodynamic analyses support the concentration-dependent activity and once-daily dosing regimen of telavancin."	( Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions. Rodvold, KA; Wenzler, E, 2015)	2.07
" While telavancin is administered daily at 10 mg/kg, the remarkably long half-lives of oritavancin and dalbavancin allow for infrequent dosing (single dose of 1200 mg for oritavancin and 1000 mg at day 1 followed by 500 mg at day 8 for dalbavancin), which could be exploited in the future for outpatient therapy."	( Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review. Van Bambeke, F, 2015)	0.87
" Neither had telavancin-related adverse events, evidence of infection at six months, nor required telavancin dosing adjustments."	( Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports. Hassoun, A; Thompson, MM, 2017)	1.04
" The safety, effectiveness and optimal dosing of telavancin for MRSA-B in this patient population are unclear."	( Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. Britt, NS; Casabar, E; McManus, D; Nizet, V; Ritchie, DJ; Sakoulas, G; Tirmizi, S; Topal, JE, 2018)	2.18
"Telavancin dosed 10 mg/kg three times weekly post-IHD or 10 mg/kg every 48 h resulted in microbiological cure in 7/8 (87."	( Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. Britt, NS; Casabar, E; McManus, D; Nizet, V; Ritchie, DJ; Sakoulas, G; Tirmizi, S; Topal, JE, 2018)	3.37
" Food and Drug Administration (FDA) recommended telavancin dosing is based on total body weight (TBW) but lacks adjusted regimens for obese subjects with varying renal function."	( Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment. Ke, M; Lin, C; Wu, W; Ye, L, 2021)	1.09
"Telavancin is a lipoglycopeptide antibiotic with limited pharmacokinetic data to guide drug dosing in patients receiving haemodialysis."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	3.51
"9 h with post-haemodialysis dosing in the control period (GMR = 0."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	2.06
" Telavancin 5 mg/kg every 48 h post-haemodialysis dosing is recommended, but dose adjustments may be warranted if haemodialysis starts within 3 h of telavancin administration."	( Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Gharibian, KN; Heung, M; Lewis, SJ; Mueller, BA; Salama, NN; Segal, JH, 2021)	2.97
"Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10 mg/kg based on total body weight but is associated with toxicities that limit its use."	( Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital. Diggs, FJ; Durham, SH; Edwards, JD; Garza, KB; Hassoun, AAM, 2022)	2.45

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
glycopeptide	Any carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (850)

Assay ID	Title	Year	Journal	Article
AID571997	Antibacterial activity against Peptostreptococcus micros by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528722	Antibacterial activity against Streptococcus viridans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524970	Antibacterial activity against vancomycin- and teichoplanin-nonsusceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524981	Antibacterial activity against Streptococcus oralis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528684	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547732	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID582852	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID524953	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus xylosus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571831	Antibacterial activity against Ruminococcus obeum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391940	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID434500	Drug level in alveolar macrophage of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID528723	Antibacterial activity against Streptococcus constellatus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547499	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547739	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524942	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571833	Antibacterial activity against Ruminococcus flavefaciens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID548215	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID572021	Antibacterial activity against Prevotella oralis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID561155	Half life in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID571823	Antibacterial activity against Catenibacterium mitsuokai by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528734	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID547748	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391949	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547960	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID572010	Antibacterial activity against Fusobacterium varium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID575725	Antimicrobial activity against Enterococcus faecalis ATCC 51299 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID434620	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID530154	AUC (0 to infinity) in human epithelial lining fluid at 750 mg administered as single dose	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
AID406253	Protein binding in rabbit at 10 mg/kg, iv	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID391974	Protein binding in human plasma	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547737	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391966	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571809	Antibacterial activity against Clostridium sordellii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571989	Antibacterial activity against Ruminococcus productus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528682	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547714	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528717	Antibacterial activity against methicillin resistant Staphylococcus aureus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID572011	Antibacterial activity against Prevotella bivia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID582841	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID524979	Antibacterial activity against Streptococcus intermedius clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID560972	Cmax in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID531934	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528859	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.5 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524958	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571814	Antibacterial activity against Clostridium sp. by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID525151	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1585404 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID582857	Drug uptake in vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID369443	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID391967	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571797	Antibacterial activity against Clostridium bartlettii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID369435	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID531718	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.12 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391955	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547733	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547738	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547735	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547989	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524985	Antibacterial activity against penicillin intermediate Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID516165	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates by CLSi method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID406240	Terminal half life in human at 10 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID396507	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 after 18 to 24 hrs by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547957	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524957	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524976	Antibacterial activity against Streptococcus sp. Group G clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID575719	Induction of VanX activity in Enterococcus faecalis ATCC 51299 expressing Van B gene assessed as UDP-MurNAc-depsipeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID571811	Antibacterial activity against Clostridium sporogenes by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571790	Antibacterial activity against Clostridium clostridioforme by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396532	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID560713	Antibacterial activity against Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID572001	Antibacterial activity against Parabacteroides distasonis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571992	Antibacterial activity against Anaerococcus prevotii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396517	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 0.5 to 50 times MIC after 24 hrs in presence of 50% human serum	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID559722	Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID547968	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391932	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID524952	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus warneri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID434494	Volume of distribution at steady state in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID559716	Antibacterial activity against Staphylococcus epidermidis RP62A after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID531959	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID572008	Antibacterial activity against Bilophila wadsworthia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547708	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524982	Antibacterial activity against Streptococcus sanguinis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID583886	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 156 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID369446	Antimicrobial activity against Streptococcus group A after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID571792	Antibacterial activity against Clostridium hathewayi by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434504	Plasma concentration in healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 24 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID516168	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID571988	Antibacterial activity against Ruminococcus lactaris by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528730	Antibacterial activity against penicillin resistant Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571830	Antibacterial activity against Ruminococcus gnavus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID560716	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus ATCC 700699 assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID572017	Antibacterial activity against Prevotella intermedia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434492	Clearance at steady state in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531925	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 16 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID575711	Induction of VanA activity in Enterococcus faecalis ATCC 51575 expressing Van B gene assessed as UDP-MurNAc-pentapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID524977	Antibacterial activity against Streptococcus bovis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524948	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus hominis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524978	Antibacterial activity against Streptococcus constellatus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528681	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 4 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547721	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID396528	Ratio of AUC in in vitro kinetic model containing Mueller-Hinton broth and methicillin-susceptible Staphylococcus aureus ATCC 13709 to MIC for methicillin-susceptible Staphylococcus aureus ATCC 13709 in bacterial killing stage	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571791	Antibacterial activity against Clostridium difficile by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571990	Antibacterial activity against Ruminococcus torques by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571998	Antibacterial activity against Streptococcus anginosus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524943	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID572023	Antibacterial activity against Sutterella wadsworthensis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID572018	Antibacterial activity against Prevotella nigrescens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID369440	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID547710	Antimicrobial activity against Streptococcus agalactiae HMC 5 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1489657	Cytotoxicity against human HK2 cells assessed as decrease in cell viability at 10 to 100 uM after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID528738	Antibacterial activity against methicillin resistant Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID559725	Antibacterial activity against methicillin-susceptible Staphylococcus aureus L2 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID547727	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528737	Antibacterial activity against methicillin resistant Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID559713	Antibacterial activity against slime-negative Staphylococcus epidermidis M7 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID559715	Antibacterial activity against slime-negative Staphylococcus epidermidis M7 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID547949	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560737	Antibacterial activity against Staphylococcus aureus assessed as bacterial count at 8 to 32 ug/ml by turbidity assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID1649286	Antibacterial activity against Vancomycin-resistant Enterococcus faecalis SR23630 (VanB) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID584094	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 453 (NRS23) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID369445	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID572014	Antibacterial activity against Prevotella P denticola by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID406261	Cmin in rabbit at 7.5 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID572012	Antibacterial activity against Prevotella buccae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547711	Antimicrobial activity against Enterococcus faecalis ATCC 29212 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560708	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 8 ug/ml by flow cytometry in presence of 0.05 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID571999	Antibacterial activity against Streptococcus constellatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547736	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID571818	Antibacterial activity against Bifidobacterium breve by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531944	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 4 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396524	Half life in in vitro kinetic model containing Mueller-Hinton broth and bacteria	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID396533	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547972	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID369438	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID528866	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547969	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID406257	AUC in rabbit at 7.5 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID525160	Antibacterial activity against vancomycin-, methicillin-resistant Staphylococcus aureus VRS1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524962	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus simulans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID548210	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528727	Antibacterial activity against Streptococcus agalactiae group B clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524939	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID525162	Antibacterial activity against vancomycin-, methicillin-resistant Staphylococcus aureus VRS3 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571996	Antibacterial activity against Peptostreptococcus anaerobius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID571789	Antibacterial activity against Clostridium bolteae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524951	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus simulans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID406265	Ratio of AUC in rabbit at 7.5 mg/kg, iv qd to MIC for Staphylococcus aureus HIP 5836 isolate	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID571822	Antibacterial activity against Bifidobacterium pseudolongum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528854	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.25 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547725	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528724	Antibacterial activity against Streptococcus oralis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1649282	Antibacterial activity against Vancomycin-resistant Staphylococcus aureus HIP11714 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID548229	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID423433	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in peritoneal dialysis fluid at 10 ug/mL administered as bolus dose 2 hrs after infection measured after 24 hrs by time-kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID434505	Ratio of drug level in alveolar macrophage to plasma of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 12 hrs after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID548231	Elimination half life in healthy human at 5 mg/kg, iv	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID575701	Induction of VanA activity in Enterococcus faecalis ATCC 51575 expressing Van B gene assessed as UDP-MurNAc-tetrapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID423437	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 in peritoneal dialysis fluid at 50 ug/mL administered as bolus dose 2 hrs after infection measured after 24 hrs by time-kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID571995	Antibacterial activity against Peptoniphilus asaccharolyticus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID582856	Drug uptake in vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID406272	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus ATCC 700788 infected New Zealand white rabbit endocarditis model assessed as bacterial count per gram of microbial vegetation at 10 mg/kg, iv administered every 24 hr	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID547987	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID525165	Antibacterial activity against linezolid/daptomycin-nonsusceptible vancomycin-susceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID548216	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID571794	Antibacterial activity against Clostridium perfringens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1649295	Antibacterial activity against Klebsiella pneumoniae SR1 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID547970	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1649290	Antibacterial activity against Vancomycin-resistant Enterococcus faecium SRM1101 (c_VanB) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID560732	Antibacterial activity against Staphylococcus aureus grown in PBS assessed as induction of bacterial membrane depolarization at 2 to 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID561178	Antibacterial activity against glycopeptide-intermediate Staphylococcus aureus NJ992 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 1 g for every 12 hrs administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID560724	Antibacterial activity against Staphylococcus aureus in presence of 5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID528862	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547953	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID434489	Tmax in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID406232	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus HIP 5836 isolate by microbroth dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID582840	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID575721	Induction of VanX activity in Enterococcus faecalis ATCC 51575 expressing Van B gene assessed as UDP-MurNAc-depsipeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID571805	Antibacterial activity against Clostridium leptum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391951	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID561171	Antibacterial activity against heteroresistant glycopeptide-intermediate Staphylococcus aureus 1629 assessed as bacterial load per gram in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID571824	Antibacterial activity against Colinsella aerofaciens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391971	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID583913	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 56 (494) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID547720	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID548223	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547723	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528685	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531694	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID369444	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID396522	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 10 times MIC after 24 hrs in PBS-nutrient depleted medium	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID516160	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as susceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID524972	Antibacterial activity against Streptococcus pyogenes clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID583885	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 56 (494) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID575709	Induction of VanA activity in Enterococcus faecalis ATCC 51299 expressing Van B gene assessed as UDP-MurNAc-pentapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID524945	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus cohnii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396550	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID369437	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID571813	Antibacterial activity against Clostridium tertium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531716	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.12 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524969	Antibacterial activity against vancomycin-susceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524975	Antibacterial activity against Streptococcus sp. Group F clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID559724	Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID583890	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 412 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID528721	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanA clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531697	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.5 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396516	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 50 times MIC after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID516162	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID571800	Antibacterial activity against Clostridium butyricum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531952	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 1 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547956	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547722	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531937	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547719	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531686	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.12 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528878	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548220	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547951	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID582859	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID561175	Antibacterial activity against methicillin-resistant Staphylococcus aureus 494 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 1 g for every 12 hrs administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID396527	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial regrowth at 40 mg/liter Cmax	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID548212	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID572015	Antibacterial activity against Prevotella P disiens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396543	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571834	Antibacterial activity against Ruminococcus luti by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531706	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.12 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571793	Antibacterial activity against Clostridium innocuum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571816	Antibacterial activity against Bifidobacterium adolescentis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID575717	Induction of VanX activity in Enterococcus faecium ATCC 51559 expressing Van A gene assessed as UDP-MurNAc-depsipeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID1649283	Antibacterial activity against Vancomycin-resistant Staphylococcus aureus HIP11983 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID531702	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.25 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID423439	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 in peritoneal dialysis fluid administered as bolus dose 2 hrs after infection measured after 24 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID571991	Antibacterial activity against Ruminococcus sp. by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396544	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571825	Antibacterial activity against Coprobacillus cateniformis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547730	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560721	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus MED2034	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID524966	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID572006	Antibacterial activity against Bacteroides vulgatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID572022	Antibacterial activity against Prevotella oris by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583893	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 435 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID528856	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.5 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID582851	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID524949	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524959	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus hominis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531931	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 4 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID369448	Antimicrobial activity against Streptococcus viridans after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID524961	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus sciuri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531913	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.12 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434614	Drug level in alveolar macrophage of healthy human undergoing fiber-optic bronchoscopy at 1g, iv twice daily for 3 days measured at 12 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531692	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524986	Antibacterial activity against penicillin resistant Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396523	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 10 times MIC after 24 hrs in MH-broth	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547740	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID396521	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 10 times MIC after 6 hrs in MH-broth	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID548224	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528728	Antibacterial activity against Streptococcus pyogenes group A clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531688	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524946	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531955	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 16 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID572004	Antibacterial activity against Bacteroides ovatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID525149	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1171063 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID575695	Induction of VanA activity in vancomycin susceptible Enterococcus faecalis BM4110 harboring Van A gene assessed as UDP-MurNAc-tetrapeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID528858	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.5 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524947	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547715	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531915	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.06 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531698	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.5 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1489656	Cytotoxicity against human HL7702 cells assessed as decrease in cell viability at 10 to 100 uM after 72 hrs by CCK8 assay	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID571819	Antibacterial activity against Bifidobacterium dentium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434508	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by standard checkerboard method in presence of 0.2 to 1 mg/ml pulmonar surfactant	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID547709	Antimicrobial activity against Streptococcus pyogenes HMC 414 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID571802	Antibacterial activity against Clostridium disporicum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391946	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID583887	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 145 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID524984	Antibacterial activity against penicillin susceptible Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571815	Antibacterial activity against Actinomyces naeslundii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528720	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanB clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524971	Antibacterial activity against vancomycin-resistant and teichoplanin-susceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID560729	Inhibition of bacterial cell wall precursor lipid 2 synthesis in Staphylococcus aureus assessed as induction of membrane depolarization at 32 ug/ml by flow cytometry in presence of fosfomycin	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID572002	Antibacterial activity against Parabacteroides merdae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528731	Antibacterial activity against penicillin intermediate Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547746	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531933	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 4 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID572000	Antibacterial activity against Streptococcus intermedius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524980	Antibacterial activity against Streptococcus mitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547741	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524965	Antibacterial activity against methicillin-resistant coagulase-negative unspeciated Staphylococcus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID391959	Cmax in human at 10 mg/kg once daily	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID560727	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry in presence of 0.5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID571807	Antibacterial activity against Clostridium paraputrificum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434503	Plasma concentration in healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 12 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID391960	AUC (0 to 24 hrs) in human at 10 mg/kg once daily	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID524956	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus cohnii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571826	Antibacterial activity against Coriobacteriumecies by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID559714	Antibacterial activity against slime-negative Staphylococcus epidermidis M7 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID548221	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID559721	Antibacterial activity against Staphylococcus aureus ATCC 35556 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID531691	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID369442	Antibacterial activity against vancomycin-resistant Enterococcus faecium after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID1143550	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition by broth microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID528719	Antibacterial activity against vancomycin resistant Enterococcus faecium VanA clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547751	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531951	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 1 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391964	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID391961	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL infected New Zealand white rabbit endocarditis model assessed as reduction in mean aortic vegetation titer at 30 mg/kg, iv twice daily after 4 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571803	Antibacterial activity against Clostridium glycolicum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1649280	Antibacterial activity against Staphylococcus aureus RN4220 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID571827	Antibacterial activity against Eggerthella lenta by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547749	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID571812	Antibacterial activity against Clostridium sporosphaeroides by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524960	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531920	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.03 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547495	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID369439	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID1489637	Antibacterial activity against vancomycin/methicillin-susceptible Staphylococcus aureus Newman ATCC 5904 after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID531953	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 1 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547707	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID575726	Antimicrobial activity against Enterococcus faecalis ATCC 51575 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID560738	Antibacterial activity against Staphylococcus aureus assessed as change in cellular membrane integrity at 8 to 32 ug/ml up to 6 hrs by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID571828	Antibacterial activity against Holdemania filiformis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583916	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 145 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID571832	Antibacterial activity against Ruminococcus albus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID547958	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524967	Antibacterial activity against vancomycin- and teichoplanin-nonsusceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524973	Antibacterial activity against Streptococcus agalactiae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1649285	Antibacterial activity against Vancomycin-resistant Enterococcus faecalis SR7914 (VanA) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID391952	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID560712	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 8 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID561177	Antibacterial activity against heteroresistant glycopeptide-intermediate Staphylococcus aureus 1629 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 1 g for every 12 hrs administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID559638	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter bacterial colonization rate at 30 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID531690	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID559719	Antibacterial activity against Staphylococcus aureus ATCC 35556 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID548211	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524983	Antibacterial activity against Streptococcus sp. clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID575724	Antimicrobial activity against Enterococcus faecium ATCC 51559 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID406268	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus ATCC 700788 infected New Zealand white rabbit endocarditis model assessed as survival at 10 mg/kg, iv administered every 24 hrs for 2 days	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID531927	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1489641	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-0649 vanA after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID524950	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus sciuri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531699	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.5 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531930	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 4 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID572005	Antibacterial activity against Bacteroides thetaiotaomicron by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID423436	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 in peritoneal dialysis fluid at 10 ug/mL administered as bolus dose 2 hrs after infection measured after 24 hrs by time-kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID528735	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID575691	Induction of VanX activity in Enterococcus faecalis ATCC 51575 expressing Van B gene at 0.3 times MIC by high-performance liquid chromatography	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID434616	Ratio of AUC (0 to 24) in epithelial lining fluid of healthy human at 10 mg/kg, iv once daily for 3 days to antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID406242	AUC in human at 7.5 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID561156	AUC (0 to 24 hrs) in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID572013	Antibacterial activity against Prevotella corporis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528857	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.5 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560722	Antibacterial activity against Staphylococcus aureus in presence of 0.05 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID391927	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571808	Antibacterial activity against Clostridium scindens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID548222	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531928	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528879	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434486	Antibacterial activity against methicillin-susceptible Staphylococcus aureus	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID575727	Induction of VanX activity in Enterococcus faecalis BM4110 expressing VanA and harboring transposon tn1546 at 0.4 times MIC by Western blotting relative to uninduced control	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID396555	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID559641	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter related infection rate at 45 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID528864	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548206	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID524963	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus warneri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1489649	Antibacterial activity against healthcare-associated methicillin-resistant/vancomycin-intermediate Staphylococcus aureus Mu50 infected in BALB/c mouse assessed as decrease in liver CFU levels at 7 mg/kg, ip administered twice in 24 hrs interval measured a	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID547747	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID548232	Protein binding healthy human serum	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531949	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1728016	Terminal half life in human at 10 mg/kg, administered as single dose measured over 2 hrs	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Polypharmacological drug actions of recently FDA approved antibiotics.
AID391965	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571801	Antibacterial activity against Clostridium celerecrescens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434607	Toxicity in healthy human at 10 mg/kg, iv once daily for 3 days by clinical laboratory test	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID547950	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID572007	Antibacterial activity against Bacteroides splanchnicus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID559723	Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID516166	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as susceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID571806	Antibacterial activity against Clostridium orbiscindens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391953	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID369441	Antibacterial activity against vancomycin-susceptible Enterococcus faecium after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID369436	Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID1489645	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-vb01 vanB after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID406252	Protein binding in rabbit at 15 mg/kg, iv	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID547966	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391957	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID524964	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus xylosus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID559718	Antibacterial activity against Staphylococcus epidermidis RP62A assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID547985	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID583895	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 453 (NRS23) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID571799	Antibacterial activity against Clostridium bifermentans by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID561174	Antibacterial activity against glycopeptide-intermediate Staphylococcus aureus NJ992 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 62 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID524954	Antibacterial activity against methicillin-susceptible coagulase-negative unspeciated Staphylococcus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528732	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID559733	Antibacterial activity against methicillin-resistant Staphylococcus aureus L83 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID575723	Antimicrobial activity against Enterococcus faecalis BM4110 expressing VanA and harboring transposon tn1546 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID560975	Antimicrobial activity against heteroresistant glycopeptide-intermediate Staphylococcus aureus 1629 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID561172	Antibacterial activity against glycopeptide-intermediate Staphylococcus aureus NJ992 assessed as bacterial load per gram in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID547706	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547986	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID434611	Plasma protein binding in healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID396529	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571994	Antibacterial activity against Finegoldia magna by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531924	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 16 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524974	Antibacterial activity against Streptococcus sp. Group C clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396505	Cmax in human serum at 7.5 mg/kg	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID572009	Antibacterial activity against Fusobacterium mortiferum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID391954	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID406260	Cmax in rabbit at 7.5 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID434615	AUC (0 to 24) in epithelial lining fluid of healthy human at 10 mg/kg, iv once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID559729	Antibacterial activity against methicillin-resistant Staphylococcus aureus L32 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID561173	Antibacterial activity against heteroresistant glycopeptide-intermediate Staphylococcus aureus 1629 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 64 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID559731	Antibacterial activity against methicillin-resistant Staphylococcus aureus L83 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID547963	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560720	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus ATCC 700698	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID547971	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID516159	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates by CLSi method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID528874	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 4 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434487	Antibacterial activity against methicillin-susceptible Streptococcus pneumoniae	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531943	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 4 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571796	Antibacterial activity against Clostridium subterminale by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID516161	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as resistant isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID369447	Antimicrobial activity against Streptococcus group B after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID528692	Antibacterial activity against Streptococcus agalactiae MED 2038 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391935	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID516164	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as susceptibility breakpoint	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID547973	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID584093	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 440 (A6298) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID561154	Cmin in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg for every 12 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID582839	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID571820	Antibacterial activity against Bifidobacterium infantis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID559642	Antimicrobial activity against Staphylococcus aureus P1 by macrodilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID434502	Ratio of drug level in alveolar macrophage to epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 8 hrs after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID571993	Antibacterial activity against Anaerococcus tetradius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID560726	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry in presence of 0.05 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID1489653	Clearance in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID572003	Antibacterial activity against Bacteroides fragilis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531917	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.06 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528729	Antibacterial activity against multidrug-resistant Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID582838	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID571821	Antibacterial activity against Bifidobacterium longum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528869	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID516169	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as resistant isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID528876	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548226	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528863	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1728017	Protein binding to human serum albumin	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Polypharmacological drug actions of recently FDA approved antibiotics.
AID531712	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531700	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.25 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391939	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528860	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396508	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 18 to 24 hrs by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528871	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391972	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID525161	Antibacterial activity against vancomycin-, methicillin-resistant Staphylococcus aureus VRS2 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1143549	Antibacterial activity against methicillin-sensitive Staphylococcus aureus MTCC 737 assessed as growth inhibition by broth microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID528686	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 1 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547976	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID559726	Antibacterial activity against methicillin-susceptible Staphylococcus aureus L2 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID575693	Induction of VanA activity in vancomycin susceptible Enterococcus faecalis BM4110 assessed as UDP-MurNAc-tetrapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID396515	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 50 times MIC after 24 hrs in presence of human albumin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID572019	Antibacterial activity against Prevotella loescheii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434509	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by standard checkerboard method in presence of 0.2 to 1 mg/ml pulmonar surfactant	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID524955	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID391944	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528718	Antibacterial activity against vancomycin resistant Enterococcus faecium VanB clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID559728	Antibacterial activity against methicillin-resistant Staphylococcus aureus L32 after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID528726	Antibacterial activity against Streptococcus mitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391970	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528873	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 4 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528733	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus hominis subsp. novobiosepticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396512	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial regrowth at 0.5 times MIC after 24 hrs in presence of human albumin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID1649289	Antibacterial activity against Vancomycin-resistant Enterococcus faecium SR23598 (VanB) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID582853	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID396530	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531711	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396545	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID1489644	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-08257 vanM after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID434617	Ratio of drug level in epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days to antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID434608	Toxicity in healthy human assessed as pulmonar inflammation at 10 mg/kg, iv once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID582858	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID584095	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 454 (NRS404) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID531710	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406408	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus HIP 5836 isolate infected New Zealand white rabbit endocarditis model assessed as bacterial count per gram of microbial vegetation at 10 mg/kg, iv administered every	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID524944	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID572016	Antibacterial activity against Prevotella P intermedia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396538	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547718	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560715	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID584085	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 435 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID571817	Antibacterial activity against Bifidobacterium bifidum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID560734	Binding affinity to cell membrane of Staphylococcus aureus grown in MHB medium at 8 ug/ml by scintillation counting relative to control	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID583891	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 38 (Mu3) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID524968	Antibacterial activity against vancomycin-resistant and teichoplanin-susceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396557	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID582846	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID396541	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547954	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID559732	Antibacterial activity against methicillin-resistant Staphylococcus aureus L83 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID571795	Antibacterial activity against Clostridium ramosum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID582845	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID571810	Antibacterial activity against Clostridium spiroforme by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583919	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 412 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 h	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID528852	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.25 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406239	Terminal half life in human at 7.5 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID391941	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID571804	Antibacterial activity against Clostridium hypermegas by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID531693	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID423434	Protein binding in mouse plasma at 0.1 to 100 ug/mL by equilibrium dialysis	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID525153	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus capitis isolate 1285355 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528736	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus auricularis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571829	Antibacterial activity against Propionibacterium propionicus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396552	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547753	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547965	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547946	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID572020	Antibacterial activity against Prevotella melaninogenica by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528691	Antibacterial activity against Enterococcus faecalis ATCC 51575 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531946	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 2 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547982	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531948	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434493	Mean residence time in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID530155	Penetration ratio, ratio of AUC in human epithelial lining fluid to fAUC in human plasma at 750 mg administered as single dose	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
AID528865	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434506	Ratio of drug level in alveolar macrophage to plasma of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 24 hrs after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID571798	Antibacterial activity against Clostridium beijerinckii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID396518	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial killing at 0.5 to 50 times MIC after 24 hrs in presence of 50% human serum	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID548214	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID575697	Induction of VanA activity in Enterococcus faecium ATCC 51559 expressing Van A gene assessed as UDP-MurNAc-tetrapeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID531926	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531947	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531958	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396511	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial killing at 50 times MIC after 24 hrs in presence of human albumin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528725	Antibacterial activity against Streptococcus intermedius clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531914	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.06 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID575705	Induction of VanA activity in vancomycin susceptible Enterococcus faecalis BM4110 harboring Van A gene assessed as UDP-MurNAc-pentapeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID547500	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547983	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531918	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.03 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531941	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 16 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548217	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID583896	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 454 (NRS404) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID584086	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 440 (A6298) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID583888	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 336 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID547984	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID525157	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus NRS1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1649279	Antibacterial activity against Staphylococcus aureus SMITH assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID560974	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 1199 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID548208	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560725	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID584092	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 435 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID434495	Cmin in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID559634	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter related infection rate at 30 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID391929	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID406237	Cmin in human at 7.5 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1489648	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 LAC infected in BALB/c mouse assessed as mouse survival rate at 7 mg/kg, ip administered as single dose measured after 10 days relative to control	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID434491	Terminal half life in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID396514	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial killing at 2.5 to 50 times MIC after 24 hrs in presence of human albumin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528693	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391933	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID396540	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531696	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.5 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528855	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.25 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID525158	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus NRS12 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID559717	Antibacterial activity against Staphylococcus epidermidis RP62A assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID406231	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus ATCC 700788 by microbroth dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID396525	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial regrowth at 5 mg/liter Cmax	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID583921	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 443 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1649284	Antibacterial activity against Enterococcus faecalis SR1004 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID547716	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID434499	Drug level in alveolar macrophage of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 12 after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID547980	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID561176	Antibacterial activity against methicillin-susceptible Staphylococcus aureus 1199 assessed as decrease in bacterial load in in vitro pharmacokinetic/pharmacodynamic model at 1 g for every 12 hrs administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID434621	Antibacterial activity against methicillin-resistant Streptococcus pneumoniae	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID528689	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 1 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524987	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1171055 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID406233	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus HIP 5836 isolate assessed as reduction of bacterial count after 24 hrs by time kill curve study	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID396542	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID561170	Antibacterial activity against methicillin-susceptible Staphylococcus aureus 1199 assessed as bacterial load per gram in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID1649292	Antibacterial activity against Streptococcus pneumoniae SR11031 (PRSP) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID528683	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434488	Cmax in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531689	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID369450	Protein binding in human plasma	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID1649291	Antibacterial activity against Streptococcus pneumoniae type 1 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID528687	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 1 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396534	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID560717	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus ATCC 700698 assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID525164	Antibacterial activity against linezolid/daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531942	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 4 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531932	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 4 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528853	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.25 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406255	Terminal half life in rabbit at 7.5 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID391963	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547961	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID406266	Ratio of AUC in rabbit at 7.5 mg/kg, iv qd to MIC for Staphylococcus aureus ATCC 700788	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID583892	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 443 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID548219	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531709	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 8 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531936	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391947	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528695	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1489642	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-06188 vanA after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID583920	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 38 (Mu3) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID547726	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531940	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 16 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406262	Cmax in rabbit at 10 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID406248	Terminal half life in rabbit at 15 mg/kg, iv	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID528877	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID516163	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as resistant isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID582836	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID547952	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547497	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID530152	Plasma protein binding in human plasma at 750 mg administered as single dose	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
AID528870	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560733	Antibacterial activity against Staphylococcus aureus grown in MHB medium assessed as induction of bacterial membrane depolarization at 2 to 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID531961	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1489643	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-0847 vanM after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID396554	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID396506	Half life in human serum at 7.5 mg/kg	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547494	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus ATCC 33591 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560719	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus ATCC 700699	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID581652	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID547988	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1489650	Half life in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID525154	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus NRS17 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547743	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547744	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547752	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID575707	Induction of VanA activity in Enterococcus faecium ATCC 51559 expressing Van A gene assessed as UDP-MurNAc-pentapeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID560728	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry in presence of 5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID1649293	Antibacterial activity against Streptococcus pneumoniae tupelo (VTSP) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID548213	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547962	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID559637	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter bacterial colonization rate at 45 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID560976	Antimicrobial activity against glycopeptide-intermediate Staphylococcus aureus NJ992 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID583914	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 152 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 h	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID391930	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547981	Antimicrobial activity against Streptococcus pyogenes HMC 414 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID396549	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547967	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547979	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531935	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID524940	Antibacterial activity against vancomycin-resistant Enterococcus	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547977	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID528851	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.12 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1143552	Antibacterial activity against vancomycin-sensitive Enterococcus faecium ATCC 19634 assessed as growth inhibition by broth microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID396531	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 1 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID396513	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as bacterial regrowth at 1 times MIC after 24 hrs in presence of human albumin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID396547	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID531929	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 8 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID531922	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 16 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548230	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1143553	Antibacterial activity against vancomycin-resistant VanA phenotype of Enterococcus faecium ATCC 51559 assessed as growth inhibition by broth microdilution method	2014	Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11	Membrane active vancomycin analogues: a strategy to combat bacterial resistance.
AID434612	Plasma concentration in healthy human undergoing fiber-optic bronchoscopy at 1g, iv twice daily for 3 days measured at 12 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531945	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 4 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396536	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID524941	Antibacterial activity against vancomycin-susceptible Enterococcus	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396553	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID391937	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531708	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391928	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID584088	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 454 (NRS404) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID406234	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus ATCC 700788 assessed as reduction of bacterial count after 24 hrs by time kill curve study	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID528688	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 1 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396509	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial regrowth at 0.25 times MIC	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528680	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 4 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434613	Drug level in epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 1g, iv twice daily for 3 days measured at 12 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID1489638	Antibacterial activity against healthcare-associated methicillin-resistant/vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID560731	Inhibition of bacterial cell wall precursor lipid 2 synthesis in Staphylococcus aureus assessed as induction of membrane depolarization at 32 ug/ml by flow cytometry in presence of bacitracin	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID560718	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus MED2034 assessed as induction of bacterial membrane depolarization at 32 ug/ml by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID547728	Antimicrobial activity against Enterococcus faecalis HMC 571 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID584087	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 453 (NRS23) infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1489651	AUClast in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID1649287	Antibacterial activity against Enterococcus faecium SR16972 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID547734	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID548225	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID560973	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 494 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID531701	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.25 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560711	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID434496	Drug level in epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 8 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID584091	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 443 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID548228	Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID434498	Drug level in alveolar macrophage of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 8 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID434497	Drug level in epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 24 hrs after start of infusion by validated liquid chromatography	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID396551	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531717	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.12 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528690	Antibacterial activity against Streptococcus pyogenes MED 2040 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547955	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID583884	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 152 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID531963	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 4 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID396548	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 2.5 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID560714	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization by flow cytometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID583889	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 360 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID406263	Cmin in rabbit at 10 mg/kg, iv administered once daily	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID531956	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 16 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID547717	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID396535	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547731	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1130 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID582847	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID396510	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial killing at 0.5 to 50 times MIC after 24 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531939	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 16 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547724	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as post-antibiotic effect at 10 times MIC pre-exposed for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531950	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 1 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406246	Protein binding in human at 10 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID406243	AUC in human at 10 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID559720	Antibacterial activity against Staphylococcus aureus ATCC 35556 assessed as inhibition of biofilm formation after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID525150	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1176127 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547959	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547964	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391950	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531916	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.06 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1649294	Antibacterial activity against Escherichia coli JC2 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID1489655	Volume of distribution at steady state in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID547729	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as post-antibiotic effect at 10 times MIC pre-exposed to Telavancin for 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391968	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531954	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 16 ug/ml after 24 hr by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID423435	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in peritoneal dialysis fluid at 50 ug/mL administered as bolus dose 2 hrs after infection measured after 24 hrs by time-kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID575699	Induction of VanA activity in Enterococcus faecalis ATCC 51299 expressing Van B gene assessed as UDP-MurNAc-tetrapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID547750	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547498	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID525155	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus NRS74 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID547496	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1307 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1649281	Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID531703	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.25 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548218	Antimicrobial activity against vancomycin-susceptible-, methicillin-resistant Staphylococcus aureus 1306 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID1649288	Antibacterial activity against Vancomycin-resistant Enterococcus faecium SR7940 (VanA) assessed as inhibition of bacterial growth incubated for 20 hrs by microdilution broth method
AID560735	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial cell lysis at 8 to 32 ug/ml by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID575703	Induction of VanA activity in vancomycin susceptible Enterococcus faecalis BM4110 assessed as UDP-MurNAc-pentapeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID559635	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter related infection rate at 15 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID575713	Induction of VanX activity in vancomycin susceptible Enterococcus faecalis BM4110 assessed as UDP-MurNAc-depsipeptide profile at 0.1 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID531704	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.12 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406406	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus HIP 5836 isolate infected New Zealand white rabbit endocarditis model assessed as sterile bacterial vegetation at 10 mg/kg, iv administered every 24 hrs for 2 days	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID396556	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 1 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547705	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 770 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531960	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 8 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID559730	Antibacterial activity against methicillin-resistant Staphylococcus aureus L32 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID528868	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560710	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 8 ug/ml by flow cytometry in presence of 5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID423438	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in peritoneal dialysis fluid administered as bolus dose 2 hrs after infection measured after 24 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate.
AID559712	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID396526	Ratio of AUC in in vitro kinetic model containing Mueller-Hinton broth and methicillin-susceptible Staphylococcus aureus ATCC 13709 to MIC for methicillin-susceptible Staphylococcus aureus ATCC 13709 in bacterial regrowth stage	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID434610	Ratio of drug level in alveolar macrophage of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days to antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID391945	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531714	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528861	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 2 ug/ml after 4 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528875	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 4 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531705	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.12 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531685	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.12 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547974	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID531687	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 0.12 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548207	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391934	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID1489654	MRT (infinity) in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID391948	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 5 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID1489652	AUC (infinity) in CD1 mouse at 5 mg/kg, iv	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID391942	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528694	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528867	Antibacterial activity against Streptococcus pyogenes MED 2040 assessed as bacterial count at 8 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID391943	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 10 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID434609	Toxicity in healthy human assessed as pulmonar infection at 10 mg/kg, iv once daily for 3 days	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID547990	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 873 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID548205	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 555 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID584090	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 336 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48 h	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID434490	AUC (0 to 24) in healthy human at 10 mg/kg, iv once daily for 3 days measured at 24 after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID531921	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.03 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID583894	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 440 (A6298) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID434507	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID560709	Antibacterial activity against Staphylococcus aureus assessed as induction of bacterial membrane depolarization at 8 ug/ml by flow cytometry in presence of 0.5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID525156	Antibacterial activity against vancomycin-intermediate methicillin-resistant Staphylococcus aureus NRS118 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID560730	Inhibition of bacterial cell wall precursor lipid 2 synthesis in Staphylococcus aureus assessed as induction of membrane depolarization at 32 ug/ml by flow cytometry in presence of D-cycloserine	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID582837	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID530153	fAUC (0 to infinity) in human plasma at 750 mg administered as single dose	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
AID525159	Antibacterial activity against vancomycin-intermediate methicillin-susceptible Staphylococcus aureus NRS56 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396539	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531695	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID548209	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID582855	Drug uptake in vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID559639	Antimicrobial activity against Staphylococcus aureus P1 infected in New Zealand rabbit assessed as decrease in catheter bacterial colonization rate at 15 mg/kg, iv (Rvb = 100%)	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.
AID391931	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 40 mg/liter after 8 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID391936	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531707	Antibacterial activity against Streptococcus agalactiae MED 2038 assessed as bacterial count at 0.12 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID583917	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 336 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 h	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID531715	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 2 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531962	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 4 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID575715	Induction of VanX activity in vancomycin susceptible Enterococcus faecalis BM4110 harboring Van A gene assessed as UDP-MurNAc-depsipeptide profile at 4 ug/ml by Western blotting	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID547713	Antimicrobial activity against Enterococcus faecium HMC 588 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID391956	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID391969	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 40 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID369449	Plasma concentration in human at 7.5 mg/kg	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID525163	Antibacterial activity against linezolid/daptomycin-nonsusceptible vancomycin-susceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID396537	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 10 mg/liter after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID525152	Antibacterial activity against daptomycin-nonsusceptible coagulase-negative Staphylococcus isolate 1285835 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID531919	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 0.03 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560723	Antibacterial activity against Staphylococcus aureus in presence of 0.5 mM D-Ala-D-Ala	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID547742	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID531713	Antibacterial activity against multidrug resistant Streptococcus pneumoniae MED 1090 assessed as bacterial count at 2 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434619	Toxicity in healthy human at 10 mg/kg/day infused over 1 hr	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID547975	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID548204	Antimicrobial activity against heterogenous vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID559727	Antibacterial activity against methicillin-susceptible Staphylococcus aureus L2 assessed as induction of biofilm eradication after 24 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
AID391938	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 20 mg/liter after 6 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID406270	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus ATCC 700788 infected New Zealand white rabbit endocarditis model assessed as sterile bacterial vegetation at 10 mg/kg, iv administered every 24 hrs for 2 days	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID575722	Antimicrobial activity against streptomycin-resistant, vancomycin-susceptible Enterococcus faecalis BM4110 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID548227	Antimicrobial activity against Streptococcus agalactiae HMC 5 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID584089	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 145 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 48	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID391962	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 20 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID528696	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID547712	Antimicrobial activity against Enterococcus faecalis HMC 571 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID396519	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial killing at 10 times MIC after 6 hrs in MH-broth	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID531957	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 2028 osteomyelitis isolate assessed as bacterial count at 16 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID406245	Protein binding in human at 7.5 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID391973	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 in MH-broth	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID583915	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 156 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID547948	Antimicrobial activity against vancomycin-resistant-, methicillin-resistant Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID547978	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1287 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID582860	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID396520	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as bacterial killing at 10 times MIC after 6 hrs in PBS-nutrient depleted medium	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID547947	Antimicrobial activity against vancomycin-intermediate-, methicillin-resistant Staphylococcus aureus 1984 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC pre-exposed to Telavancin for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID406250	AUC in rabbit at 15 mg/kg, iv	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID561169	Antibacterial activity against methicillin-resistant Staphylococcus aureus 494 assessed as bacterial load per gram in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg administered daily after 96 hrs	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
AID396546	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as change in bacterial burden at 5 mg/liter after 4 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID516167	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as resistant isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID547745	Antimicrobial activity against Enterococcus faecium HMC 588 assessed as time required to induce sub-MIC effect at 0.2 times MIC exposed for 2 hrs by plate counting method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Postantibiotic effects of telavancin against 16 gram-positive organisms.
AID406236	Cmax in human at 7.5 mg/kg, iv administered every 24 hrs	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID531923	Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 35984 assessed as bacterial count at 16 ug/ml after 8 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID531938	Antibacterial activity against methicillin resistant Staphylococcus aureus MED 1805 bloodstream isolate assessed as bacterial count at 16 ug/ml after 24 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528872	Antibacterial activity against Enterococcus faecalis ATCC 51575 assessed as bacterial count at 4 ug/ml after 2 hrs by time-kill assay	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID434501	Ratio of drug level in alveolar macrophage to epithelial lining fluid of healthy human undergoing fiber-optic bronchoscopy at 10 mg/kg, iv once daily for 3 days measured at 4 hrs after start of infusion	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID583918	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 360 infected in neutropenic BALB/c mouse lung infection model assessed as reduction of CFU at 40 mg/kg, ip administered every 12 hrs measured after 24 h	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID406274	Antibacterial activity against glycopeptide-intermediate resistant Staphylococcus aureus HIP 5836 isolate infected New Zealand white rabbit endocarditis model assessed as survival at 10 mg/kg, iv administered every 24 hrs for 2 days	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
AID575728	Induction of D,D-dipeptidase activity in Enterococcus faecalis BM4110 expressing VanA and harboring transposon tn1546 at 0.4 times MIC by Western blotting relative to uninduced control	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
AID391958	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 13709 assessed as change in bacterial burden at 2.5 mg/liter after 2 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.
AID434618	fAUC (0 to 24) in mouse pneumonia model at 40 mg/kg	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID575690	Induction of VanX activity in Enterococcus faecalis ATCC 51299 expressing Van B gene at 0.3 times MIC by high-performance liquid chromatography	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	75 (30.86)	29.6817
2010's	157 (64.61)	24.3611
2020's	11 (4.53)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	29 (11.84%)	5.53%
Reviews	47 (19.18%)	6.00%
Case Studies	13 (5.31%)	4.05%
Observational	1 (0.41%)	0.25%
Other	155 (63.27%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry [NCT01130324]		0 participants (Actual)	Observational [Patient Registry]	2009-11-30	Withdrawn(stopped due to Released by he FDA from this Post-Marketing Commitment)
A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin [NCT01238796]	Phase 1	45 participants (Actual)	Interventional	2010-12-31	Completed
A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphy [NCT00107978]	Phase 3	1,035 participants (Actual)	Interventional	2005-02-28	Completed
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus [NCT00124020]	Phase 3	771 participants (Actual)	Interventional	2005-01-31	Completed
Telavancin Observational Use Registry (TOUR) [NCT02288234]		1,063 participants (Actual)	Observational	2014-11-30	Completed
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus [NCT00107952]	Phase 3	761 participants (Actual)	Interventional	2005-02-28	Completed
A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections (Gram Positive cSSSI) [NCT00077675]	Phase 2	201 participants (Actual)	Interventional	2004-02-29	Completed
A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphy [NCT00091819]	Phase 3	862 participants (Actual)	Interventional	2005-01-31	Completed
A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia [NCT00062647]	Phase 2	60 participants (Actual)	Interventional	2003-08-31	Completed
A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) [NCT00061633]	Phase 2	169 participants (Actual)	Interventional	2003-06-30	Completed
Pharmacokinetics of Telavancin in Normal and Obese Subjects [NCT02753855]	Phase 1	32 participants (Actual)	Interventional	2016-04-30	Completed
An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 3 Months to 17 Years [NCT02013141]	Phase 4	22 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to FDA waived the pediatric study requirement for this application)
Phase II, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients [NCT01321879]	Phase 2	40 participants (Actual)	Interventional	2011-03-31	Completed
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 [NCT02392208]	Phase 4	8 participants (Actual)	Interventional	2015-07-31	Completed
Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations [NCT03172793]	Phase 4	18 participants (Actual)	Interventional	2017-08-08	Completed
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With Subarachnoid Hemorrhage [NCT06119061]	Phase 4	20 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis [NCT02208063]	Phase 3	121 participants (Actual)	Interventional	2014-12-31	Terminated(stopped due to Halted due to lack of statistical power. No safety concerns identified.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial	Outcome
NCT00061633 (1) [back to overview]	Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population
NCT00062647 (1) [back to overview]	Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With Bacteremia, Metastatic Complications, or Positive Culture at the Test of Cure Evaluation
NCT00077675 (1) [back to overview]	Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population
NCT00091819 (1) [back to overview]	Clinical Response
NCT00107952 (1) [back to overview]	Clinical Response
NCT00107978 (1) [back to overview]	Clinical Response
NCT00124020 (1) [back to overview]	Clinical Response
NCT01321879 (1) [back to overview]	Patient Clinical Response to Telavancin
NCT02208063 (4) [back to overview]	Investigator Clinical Response (Success or Failure) at EOT in the Microbiological All-treated (mAT) Population
NCT02208063 (4) [back to overview]	Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)
NCT02208063 (4) [back to overview]	Number of Participants With an Investigator Clinical Outcome of Cure at TOC in the Microbiological All-treated (mAT) Population
NCT02208063 (4) [back to overview]	Number of Participants With the Development of a New Metastatic Foci of S. Aureus Infection at Test of Cure (TOC) in the Microbiological All-treated (mAT) Populations
NCT02392208 (6) [back to overview]	AUC0-24 of Telavancin
NCT02392208 (6) [back to overview]	AUC24-48 of Telavancin
NCT02392208 (6) [back to overview]	CLobs of Telavancin
NCT02392208 (6) [back to overview]	Cmax of Telavancin
NCT02392208 (6) [back to overview]	t1/2 of Telavancin
NCT02392208 (6) [back to overview]	Vss of Telavancin

Intervention	participants (Number)
	Cured	Failure	Indeterminate
Standard of Care for cSSSI	66	3	0
Telavancin	66	6	0

Intervention	participants (Number)
	Cured	Failure
Standard Therapy	8	1
Telavancin	7	1

Intervention	participants (Number)
	Cured	Failure
Standard of Care for cSSSI	72	5
Telavancin	74	3

Intervention	participants (Number)
	Cure	Not cured	Indeterminate	Missing
Telavancin	323	52	23	28
Vancomycin	321	58	16	34

Intervention	participants (Number)
	Cured	Failure	Indeterminate	Missing
Telavancin	214	46	56	56
Vancomycin	221	68	41	44

Intervention	patients (Number)
	Cure	Not cured	Indeterminate	Missing
Telavancin	358	59	17	24
Vancomycin	364	57	20	40

Intervention	participants (Number)
	Cured	Failure	Indeterminate	Missing
Telavancin	227	53	39	58
Vancomycin	228	52	38	62

Intervention	Participants (Count of Participants)
Telavancin	32

Intervention	Participants (Count of Participants)
	Success	Failure	Indeterminate	Missing
Standard of Care	36	15	0	1
Telavancin	28	13	5	1

Intervention	Participants (Count of Participants)
	Cure	Failure	Indeterminate
Standard of Care	27	21	4
Telavancin	22	19	6

Intervention	Participants (Count of Participants)
	Cure	Failure	Indeterminate	Missing
Standard of Care	31	19	0	2
Telavancin	26	15	3	3

Intervention	Participants (Count of Participants)
	Yes	No	Indeterminate
Standard of Care	3	41	8
Telavancin	6	32	9

Intervention	mcg*h/mL (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	307	465

Intervention	mcg*h/mL (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	121	220

Intervention	mL/h/kg (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	11.8	6.1

Intervention	mcg/mL (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	33.1	38.1

Intervention	hours (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	13.4	21.4

Intervention	mL/kg (Mean)
	Period 1: Telavancin Before Hemodialysis	Period 2: Telavancin After Hemodialysis
All Study Participants	201	172

Substance	Relationship Strength	Studies	Trials	Classes	Roles
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.04	1	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.04	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.1	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.04	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.04	1	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.04	1	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.04	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.04	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.04	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.04	1	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alfuzosin alfuzosin: structure given in first source	2.04	1	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	2.04	1	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.04	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.04	1	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.04	1	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	2.04	1	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
theophylline [no description available]	2.04	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.04	1	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.04	1	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.04	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.04	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.04	1	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.04	1	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.04	1	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.04	1	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	8.86	2	1
betaxolol [no description available]	2.04	1	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bevantolol bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.	2.04	1	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	2.04	1	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.04	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bromazepam Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.	2.04	1	0	organic molecular entity
bromopride bromopride: RN given refers to parent cpd; structure	2.04	1	0	benzamides
brotizolam brotizolam: structure	2.04	1	0	organic molecular entity
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.04	1	0	aromatic ketone
bumetanide [no description available]	2.04	1	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.04	1	0	quinazolines
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	2.04	1	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
busulfan [no description available]	2.04	1	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
caffeine [no description available]	2.04	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.04	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
metrizoate Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.	2.04	1	0	monocarboxylic acid	radioopaque medium
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.04	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carvedilol [no description available]	2.04	1	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.04	1	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	2.04	1	0	benzodiazepine
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.04	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.04	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.04	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.04	1	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	2.04	1	0	isoindoles; monochlorobenzenes; sulfonamide
cifenline [no description available]	2.04	1	0	diarylmethane
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.04	1	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	4.67	8	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.04	1	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.04	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	2.04	1	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.04	1	0	clonidine; imidazoline
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	2.04	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
dapsone [no description available]	2.04	1	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.04	1	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.04	1	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.04	1	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.04	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.04	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.04	1	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	2.04	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.04	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.04	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	2.04	1	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	2.04	1	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	2.04	1	0	dibenzooxepine; tertiary amino compound	antidepressant
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	2.04	1	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.04	1	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	2.04	1	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
etilefrine Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.	2.04	1	0	phenols
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.04	1	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.04	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma	2.04	1	0	azaspiro compound
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.04	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.04	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.04	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.04	1	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.04	1	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.04	1	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	2.04	1	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.04	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.04	1	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.04	1	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	2.04	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	7.75	3	0
glimepiride glimepiride: structure given in first source	2.04	1	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.04	1	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.04	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
granisetron [no description available]	2.04	1	0	aromatic amide; indazoles
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	2.04	1	0	acetamides
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.04	1	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.04	1	0	barbiturates
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	2.04	1	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	2.04	1	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.04	1	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	2.04	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hypericin [no description available]	2.04	1	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.04	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.04	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	2.04	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.04	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.04	1	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.04	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.04	1	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	2.04	1	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.04	1	0	organic molecular entity
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.04	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.04	1	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.04	1	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.04	1	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	2.04	1	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.04	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.04	1	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.04	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	2.04	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.04	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.04	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
letrozole [no description available]	2.04	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	2.04	1	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.04	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.04	1	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.04	1	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	2.04	1	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	2.04	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	2.04	1	0	organic molecular entity
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	2.04	1	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.04	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	2.04	1	0	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	2.04	1	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.04	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.04	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	2.04	1	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	2.04	1	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	7.74	3	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.04	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	8.84	2	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
milrinone [no description available]	2.04	1	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	2.04	1	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.04	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.04	1	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.04	1	0	acetamides; benzamides	anti-arrhythmia drug
naratriptan naratriptan: structure given in first source	2.04	1	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	2.04	1	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.04	1	0	benzoxazocine; tertiary amino compound
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.04	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.04	1	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.04	1	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.04	1	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	2.04	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.04	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.04	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nizatidine [no description available]	2.04	1	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.04	1	0	isoquinolines	dopamine uptake inhibitor
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.04	1	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.04	1	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.04	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	2.04	1	0	carbazoles
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxiracetam oxiracetam: structure in first source	2.04	1	0	organonitrogen compound; organooxygen compound
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.04	1	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
pamidronate [no description available]	2.04	1	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.04	1	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.04	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.04	1	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.04	1	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	2.04	1	0	oxopurine
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.04	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.04	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.04	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
moxonidine moxonidine: structure given in first source	2.04	1	0	organohalogen compound; pyrimidines
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.04	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	2.04	1	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
piretanide piretanide: potent inhibitor of chloride transport; structure	2.04	1	0	aromatic ether
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.04	1	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.	2.04	1	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.04	1	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2.04	1	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.04	1	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	2.04	1	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	2.04	1	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.04	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.04	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.04	1	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.04	1	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.04	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
pyridostigmine [no description available]	2.04	1	0	pyridinium ion
pyrimethamine Maloprim: contains above 2 cpds	2.04	1	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.04	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine [no description available]	2.04	1	0	aralkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.04	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	2.04	1	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	2.04	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.04	1	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.04	1	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
imatinib [no description available]	2.04	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.04	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.44	2	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.04	1	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.04	1	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	2.04	1	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.04	1	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.04	1	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.04	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
temozolomide [no description available]	2.04	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	2.04	1	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.04	1	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.04	1	0	phthalimides; piperidones
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.04	1	0	aziridines
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	2.04	1	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	2.04	1	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.04	1	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	2.04	1	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	2.04	1	0	amino acid
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	2.04	1	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.04	1	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.04	1	0	triazolobenzodiazepine	sedative
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.76	3	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	2.04	1	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	2.04	1	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
urapidil [no description available]	2.04	1	0	piperazines
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	2.04	1	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
viloxazine Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.	2.04	1	0	aromatic ether
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	2.04	1	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	2.04	1	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.04	1	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.04	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.04	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.98	4	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.04	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
vincristine [no description available]	2.04	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.04	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.04	1	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.04	1	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.04	1	0	kanamycins	bacterial metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.04	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	4.41	6	0	penicillin allergen; penicillin	antibacterial drug
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.04	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	3.44	7	0	penicillin	antibacterial agent; antibacterial drug
sodium citrate, anhydrous Sodium Citrate: Sodium salts of citric acid that are used as buffers and food preservatives. They are used medically as anticoagulants in stored blood, and for urine alkalization in the prevention of KIDNEY STONES.. sodium citrate : The trisodium salt of citric acid.	2.07	1	0	organic sodium salt	anticoagulant; flavouring agent
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.14	5	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.04	1	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
dichloroacetic acid [no description available]	2.04	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.04	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	2.04	1	0	penicillin allergen; penicillin
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	2.04	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	3.43	1	1	penicillanic acids
acrylonitrile [no description available]	2.05	1	0	aliphatic nitrile; volatile organic compound	antifungal agent; carcinogenic agent; fungal metabolite; mutagen; polar aprotic solvent
n-decyl alcohol n-decyl alcohol: RN given refers to parent cpd. decanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of ten carbon atoms.. decan-1-ol : A fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of ten carbon atoms.	2.05	1	0	decanol; primary alcohol	metabolite; pheromone; protic solvent
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	2.04	1	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.04	1	0	bromide salt
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	7.73	3	0	penicillin allergen; penicillin	antibacterial drug
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	2.04	1	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	4.13	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.03	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pirinitramide Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.	2.04	1	0	nitrile
edrophonium bromide [no description available]	2.04	1	0
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.04	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	2.04	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.04	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	2.04	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone ketobemidone: structure	2.04	1	0	piperidines
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	2.04	1	0	thiazoles
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.04	1	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
lithium carbonate Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.	2.04	1	0	carbonate salt; lithium salt	antimanic drug
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.04	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.96	4	0	cyclic ketone; erythromycin
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.04	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
lormetazepam lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine [no description available]	2.04	1	0
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.04	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	15.43	104	16	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
metylperon metylperon: RN given refers to parent cpd	2.04	1	0	aromatic ketone
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	2.04	1	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	2.04	1	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.04	1	0	aromatic ketone
chlordesmethyldiazepam [no description available]	2.04	1	0	benzodiazepine
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.04	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.04	1	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	2.04	1	0	dichlorobenzene; penicillin	antibacterial drug
streptomycin [no description available]	2.04	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
cladribine [no description available]	2.04	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	2.04	1	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
terodiline [no description available]	2.04	1	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene 1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd	2.04	1	0
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.15	1	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.04	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
metocurine iodide [no description available]	2.04	1	0	aromatic ether
apazone Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.	2.04	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.04	1	0	selegiline; terminal acetylenic compound	geroprotector
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	2.04	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
cephapirin Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.	2.04	1	0	cephalosporin	antibacterial drug
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.04	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
du-21220 Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.	2.04	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	7.44	2	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.04	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.04	1	0	tryptamines
toloxatone toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.	2.04	1	0	oxazolidinone; primary alcohol; toluenes
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.04	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
sisomicin Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
amdinocillin Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.	2.04	1	0	penicillin	antibacterial drug; antiinfective agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.04	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.04	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.04	1	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
trimazosin trimazosin: RN given refers to parent cpd; structure	2.04	1	0	N-arylpiperazine
ribavirin Rebetron: Rebetron is tradename	2.04	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.04	1	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.04	1	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol [no description available]	2.04	1	0
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.04	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.04	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.	2.04	1	0	penicillin
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.04	1	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.04	1	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.04	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
meptazinol Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.	2.04	1	0	azepanes
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	2.04	1	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	2.04	1	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol medroxalol: RN given refers to parent cpd without isomeric designation	2.04	1	0	salicylamides
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	2.04	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	2.04	1	0	cephalosporin	antibacterial drug
lorcainide [no description available]	2.04	1	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.04	1	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.	2.04	1	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	8.83	2	1	penicillin allergen; penicillin	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.04	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	2.04	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	2.04	1	0	cephalosporin	antibacterial drug
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
moxalactam Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.	2.04	1	0	cephalosporin; oxacephem	antibacterial drug
endralazine BQ 22-708: RN given refers to parent cpd	2.04	1	0	benzamides
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.04	1	0	cephalosporin	antibacterial drug
encainide Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.	2.04	1	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.04	1	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	2.04	1	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	2.04	1	0
recainam recainam: structure given in first source	2.04	1	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.04	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.04	1	0	aminopyridine
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.04	1	0	aromatic ketone
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.04	1	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.04	1	0	dimethoxybenzene
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.04	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.04	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	2.04	1	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
trospectomycin trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer	2.04	1	0	dioxanes
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.04	1	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
sematilide sematilide: RN refers to HCl; structure given in first source	2.04	1	0
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	2.04	1	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	2.04	1	0	quinolines
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.04	1	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source	2.04	1	0	organic molecular entity
sparfloxacin [no description available]	2.04	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.04	1	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	2.04	1	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.04	1	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.04	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.04	1	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.04	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	2.04	1	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.04	1	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	2.04	1	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
lamivudine [no description available]	2.04	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
irinotecan [no description available]	2.04	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.04	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.04	1	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	2.04	1	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.04	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	2.04	1	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	2.04	1	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
cisatracurium cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R,2'R)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
fosinoprilat fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.	2.04	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.04	1	0
cefprozil [no description available]	2.04	1	0	cephalosporin; semisynthetic derivative	antibacterial drug
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.04	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	7.82	14	0	cephalosporin	fungal metabolite
imipramine n-oxide imipramine N-oxide: RN given refers to parent cpd; structure	2.04	1	0	dibenzooxazepine
fropenem [no description available]	2.05	1	0	faropenem
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	2.04	1	0	glutamic acid derivative
intoplicine intoplicine: structure in first source	2.04	1	0	pyridoindole
repaglinide [no description available]	2.04	1	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.04	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.04	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
ethinyl estradiol-17-sulfate ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer	2.04	1	0
ethinylestradiol-3-sulfate ethinylestradiol-3-sulfate: binds to albumin at 2 sites	2.04	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
cefcanel cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure	2.04	1	0
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.04	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride epristeride: structure given in first source	2.04	1	0	steroid acid
talinolol [no description available]	2.04	1	0	ureas
denaverine denaverine: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
diprafenone diprafenone: structure given in first source	2.04	1	0	aromatic compound
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	2.04	1	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	2.04	1	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.04	1	0	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	2.04	1	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.04	1	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.04	1	0	organonitrogen compound; organooxygen compound
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.04	1	0	benzofurans
panipenem panipenem: synthetic cpd; structure given in first source	2.04	1	0	organic molecular entity
perindoprilat perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.	2.04	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine [no description available]	2.04	1	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.04	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
9-aminocamptothecin [no description available]	2.04	1	0	pyranoindolizinoquinoline
sch 34343 Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer	2.04	1	0
squalamine squalamine: from dogfish shark Squalus acanthias; structure given in first source	2.04	1	0	bile acid
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	4.06	2	0	carbapenems
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	6.51	18	0	carbamate ester; oxazolidinone	metabolite
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.04	1	0	hydroxy-1,2-naphthoquinone
rivastigmine [no description available]	2.04	1	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	2.04	1	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	2.04	1	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	2.04	1	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.04	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.04	1	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	2.06	1	0	iditol	fungal metabolite
mci 9038 [no description available]	2.04	1	0	peptide
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.46	2	0
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.46	2	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.04	1	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
asulacrine asulacrine: derivative of amsacrine; structure given in first source	2.04	1	0	acridines
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.	2.04	1	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine 2-hydroxyimipramine: RN given refers to parent cpd	2.04	1	0	dibenzoazepine
ecteinascidin 743 [no description available]	2.04	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	2.04	1	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	2.04	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
gefitinib [no description available]	2.04	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate [no description available]	2.04	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
tamsulosin [no description available]	2.04	1	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
sulbactam [no description available]	2.04	1	0	penicillanic acids
dilevalol (R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.	2.04	1	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
carbapenems [no description available]	4.06	2	0
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	4.35	3	0	beta-lactam antibiotic allergen; beta-lactam
docetaxel [no description available]	2.04	1	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
irofulven irofulven: structure in first source	2.04	1	0	cyclohexenones
ym 872 YM 872: structure in first source	2.04	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.14	5	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	4.35	3	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
dx 8951 [no description available]	2.04	1	0	pyranoindolizinoquinoline
cilomilast [no description available]	2.04	1	0	methoxybenzenes
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	2.04	1	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan tezosentan: structure in first source	2.04	1	0
sabarubicin sabarubicin: structure given in first source	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	4.11	3	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	2.04	1	0	dihydropyridine
solifenacin [no description available]	2.04	1	0	isoquinolines
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.04	1	0	morpholines
an-69 AN-69: copolymer of acrylonitrile & sodium methallylsulfonate used in hemodialysis	2.05	1	0
abanoquil [no description available]	2.04	1	0
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	2.04	1	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
temocillin temocillin: beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source. temocillin : A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.	3.15	1	0	penicillin
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.04	1	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	2.04	1	0	piperidinecarboxamide; ropivacaine	local anaesthetic
melagatran [no description available]	2.04	1	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
tesaglitazar tesaglitazar: structure in first source	2.04	1	0
iclaprim iclaprim: has antiviral activity. iclaprim : A racemate consisting of equimolar amounts of (R)- and (S)-iclaprim. Both enantiomers exhibit similar, potent bactericidal activity against major Gram-positive pathogens, notably methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA, respectively).. 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine : An aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl group.	5.09	5	0	aminopyrimidine; chromenes; cyclopropanes
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.04	1	0
fosfluconazole fosfluconazole: prodrug of fluconazole	2.04	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
cp 101,606 traxoprodil mesylate: a selective NMDA antagonist; structure given in first source	2.04	1	0
nsc-89199 estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.	2.04	1	0	carbamate ester; organochlorine compound; steroid phosphate
phenethicillin phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.	2.04	1	0	penicillin allergen; penicillin
acivicin [no description available]	2.04	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	3.35	1	0
bortezomib [no description available]	2.04	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.04	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	7.98	4	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.04	1	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.04	1	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	2.04	1	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.04	1	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.04	1	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	2.04	1	0
miglitol [no description available]	2.04	1	0	piperidines
linezolid [no description available]	6.74	23	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
tolterodine [no description available]	2.04	1	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	2.04	1	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.04	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.05	1	0	cyclodextrin
acarbose [no description available]	2.04	1	0	amino cyclitol; glycoside
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.04	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.04	1	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	2.04	1	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.04	1	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	4.76	9	0
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	2.47	2	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.04	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
bms 214662 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.	2.04	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
eptifibatide [no description available]	2.04	1	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.04	1	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine [no description available]	2.04	1	0	2'-deoxyribonucleoside
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.04	1	0
teniposide [no description available]	2.04	1	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.04	1	0	carbohydrate derivative; nucleobase-containing molecular entity
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	2.04	1	0	cephalosporin; semisynthetic derivative	antibacterial drug
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2.04	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.04	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.04	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.04	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	2.04	1	0	kanamycins	antibacterial agent; protein synthesis inhibitor
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	2.04	1	0	antibiotic antifungal drug; echinocandin	antiinfective agent
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	2.04	1	0	penicillin allergen; penicillin	antibacterial drug
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	2.04	1	0	indolyl carboxylic acid
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.04	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	2.04	1	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.04	1	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	2.04	1	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.04	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.04	1	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.04	1	0	isoquinolines
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.04	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
cancidas [no description available]	2.04	1	0
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.05	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	2.04	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.04	1	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
hmr 3647 [no description available]	2.73	3	0
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	2.04	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine [no description available]	2.04	1	0	aromatic ether
dolasetron [no description available]	2.04	1	0	indolyl carboxylic acid
or 1259 [no description available]	2.04	1	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.04	1	0	steroid	estrogen
quinine [no description available]	2.04	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
isepamicin [no description available]	2.04	1	0
ifetroban ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative	2.04	1	0	benzenes; monocarboxylic acid
lamifiban lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass	2.04	1	0	N-acylglycine
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.04	1	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	2.04	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin [no description available]	2.04	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.04	1	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	2.04	1	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	2.04	1	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	2.04	1	0	isoquinolines
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.04	1	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	2.04	1	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.04	1	0	homodetic cyclic peptide
indocyanine green [no description available]	2.04	1	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
codeine [no description available]	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.04	1	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.04	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	2.04	1	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.04	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
cicaprost cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R,4R),5beta,6aalpha))-isomer	2.04	1	0	monoterpenoid
dexmedetomidine [no description available]	2.04	1	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.04	1	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	2.04	1	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	2.04	1	0	phenylalanine derivative
vinorelbine [no description available]	2.04	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.04	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.04	1	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.04	1	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.04	1	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.04	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.04	1	0	phenanthrenes
cefixime [no description available]	2.04	1	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.04	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.04	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	2.04	1	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefuroxime [no description available]	2.73	3	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	4.34	4	1	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.45	2	0	cephalosporin; oxime O-ether	antibacterial drug
hr 810 cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.04	1	0	cephalosporin; cyclopentapyridine
ceftazidime [no description available]	2.04	1	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefetamet cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.	2.04	1	0	cephalosporin
famotidine [no description available]	2.04	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	2.04	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	2.04	1	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
ginkgolide b [no description available]	2.04	1	0
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	2.04	1	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.04	1	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
eniporide eniporide: inhibits NHE-1 isoform; structure in first source	2.04	1	0
cilastatin [no description available]	2.04	1	0	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
ixabepilone [no description available]	2.04	1	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	2.04	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
verlukast verlukast: LTD4 receptor antagonist	2.04	1	0
ceftizoxime [no description available]	2.04	1	0	cephalosporin	antibacterial drug
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	2.04	1	0	monobactam	antibacterial drug
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	2.04	1	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.04	1	0	lipid As
dantrolene [no description available]	2.04	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.04	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2.04	1	0	diarylmethane
napsagatran napsagatran: structure given in first source	2.04	1	0
temsirolimus [no description available]	2.04	1	0	macrolide lactam
bms188797 [no description available]	2.04	1	0
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.04	1	0	imidazolidine-2,4-dione
tomopenem [no description available]	2.04	1	0
bb-83698 BB-83698: peptide deformylase inhibitor	2.04	1	0
zotarolimus zotarolimus: synthetic analog of rapamycin; structure in first source	2.04	1	0	lactam; macrolide
gentamicin sulfate [no description available]	3.3	6	0
bn 52020 [no description available]	2.04	1	0
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	7.72	2	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
vindesine [no description available]	2.04	1	0
ru 66647 telithromycin: a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;	2.07	1	0
scopolamine hydrobromide [no description available]	2.04	1	0
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	5.06	7	0
bisaramil [no description available]	2.04	1	0
teicoplanin teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.	2.04	1	0
ly-146032 [no description available]	5.22	11	1	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin [no description available]	2.47	2	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	7.69	21	0	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	2.05	1	0
piperacillin, tazobactam drug combination Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.	3.43	1	1
quinupristin-dalfopristin quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively	5.06	7	0	organic molecular entity
uridine diphosphate n-acetylmuramic acid Uridine Diphosphate N-Acetylmuramic Acid: A nucleoside diphosphate sugar which is formed from UDP-N-acetylglucosamine and phosphoenolpyruvate. It serves as the building block upon which peptidoglycan is formed.. UDP-N-acetyl-alpha-D-muramate(3-) : A UDP-N-acetyl-D-muramate(3-) in which the anomeric centre of the pyranose fragment has alpha-configuration.	2.05	1	0	UDP-N-acetylmuramate(3-)
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	2.04	1	0	oligopeptide	antineoplastic agent; GnRH antagonist
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	3.2	5	0
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.96	4	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	2.04	1	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.04	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	5.79	11	0
roquinimex roquinimex: structure in first source	2.04	1	0	aromatic amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.04	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.04	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.04	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.04	1	0	benzenes; hydroxycoumarin; methyl ketone
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	2.04	1	0
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.04	1	0
tigecycline [no description available]	6.02	14	0
omadacycline omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source	7.72	2	0	tetracyclines
eravacycline eravacycline: has antibacterial activity	7.72	2	0	tetracyclines
daptomycin [no description available]	7.45	32	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.06	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.04	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	9.68	8	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.04	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.04	1	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.04	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	2.04	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.04	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.04	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	2.04	1	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.04	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	2.04	1	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	2.04	1	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.04	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.04	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	5.94	8	0	cephalosporin; thiadiazoles	antimicrobial agent
rifabutin [no description available]	2.04	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).	0	2.43	2	0
Infections, Staphylococcal [description not available]	0	13.95	73	6
Bacterial Endocarditides [description not available]	0	4.79	11	0
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	0	4.79	11	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	13.95	73	6
Bacterial Infections, Gram-Positive [description not available]	0	14.75	57	9
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	1	21.75	57	9
Staphylococcal Pneumonia [description not available]	0	14.74	14	3
Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.	0	9.74	14	3
Cystic Fibrosis of Pancreas [description not available]	0	3.73	3	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	8.73	3	0
Catheter-Associated Infections [description not available]	0	5.49	5	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	7.26	16	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	3.69	3	0
Pneumonia Infection of the lung often accompanied by inflammation.	0	3.69	3	0
Extravascular Hemolysis [description not available]	0	2.1	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.1	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	5.27	4	1
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	1	11.02	17	2
Chronic Kidney Diseases [description not available]	0	3.23	1	0
Chronic Kidney Failure [description not available]	0	5.93	4	2
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	5.93	4	2
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	1	5.23	1	0
DRESS Syndrome [description not available]	0	2.31	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	4.19	3	1
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	3.95	2	1
Hospital Acquired Pneumonia [description not available]	0	2.63	2	0
Healthcare-Associated Pneumonia Infection of the lung often accompanied by inflammation that is acquired through an interaction within a healthcare institution often through a therapeutic experience (e.g., use of catheters or ventilators).	0	2.63	2	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	7.31	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	3.95	2	1
2019 Novel Coronavirus Disease [description not available]	0	2.31	1	0
Ventilator-Associated Pneumonia [description not available]	0	6.71	6	2
Pneumonia, Ventilator-Associated Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.	0	6.71	6	2
Adverse Drug Event [description not available]	0	3.45	2	0
Bacterial Disease [description not available]	0	5.28	4	1
Bacterial Infections Infections by bacteria, general or unspecified.	1	7.28	4	1
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	0	3.49	7	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.45	2	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	3.06	1	0
Arthropathies [description not available]	0	2.15	1	0
Joint Diseases Diseases involving the JOINTS.	0	2.15	1	0
Health Care Associated Infection [description not available]	0	12.16	28	5
Cross Infection Any infection which a patient contracts in a health-care institution.	0	12.16	28	5
Allergy, Drug [description not available]	0	2.17	1	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	2.17	1	0
Bacterial Pneumonia [description not available]	0	11.88	10	1
Infections, Staphylococcal Skin [description not available]	0	10.67	13	4
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	1	12.67	13	4
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	1	8.88	10	1
Acute Kidney Failure [description not available]	0	5.12	3	1
Interstitial Nephritis [description not available]	0	2.21	1	0
Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.	0	2.21	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	10.12	3	1
Mediastinitis Inflammation of the mediastinum, the area between the pleural sacs.	0	2.08	1	0
Benign Neoplasms [description not available]	0	3.71	3	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.71	3	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.49	2	0
Infections, Pseudomonas [description not available]	0	3.39	2	0
Infections, Respiratory [description not available]	0	2.1	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	3.39	2	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	2.1	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.1	1	0
Infectious Skin Diseases [description not available]	0	10.62	12	8
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	0	10.62	12	8
Infections, Soft Tissue [description not available]	0	6.06	4	1
Bacterial Infections, Gram-Negative [description not available]	0	4.82	2	1
Bacterial Skin Diseases [description not available]	0	8.43	12	4
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	4.82	2	1
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	8.43	12	4
Soft Tissue Infections Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)	0	6.06	4	1
Co-infection [description not available]	0	3.88	2	1
Recrudescence [description not available]	0	4.43	1	1
Hematologic Malignancies [description not available]	0	4.43	1	1
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	4.43	1	1
Infective Endocarditis [description not available]	0	2.49	2	0
Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.	0	2.49	2	0
Infection, Postoperative Wound [description not available]	0	7.47	4	4
Dysgeusia A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.	0	4.4	2	2
Skin Diseases, Viral Skin diseases caused by viruses.	0	2.05	1	0
Hepatic Insufficiency Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.	0	3.44	1	1
Community Acquired Infection [description not available]	0	3.83	2	1
Group A Strep Infection [description not available]	0	2.06	1	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	0	2.06	1	0
Paraparesis Mild to moderate loss of bilateral lower extremity motor function, which may be a manifestation of SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; MUSCULAR DISEASES; INTRACRANIAL HYPERTENSION; parasagittal brain lesions; and other conditions.	0	2.06	1	0
Acute Generalised Exanthematous Pustulosis [description not available]	0	2.06	1	0
Dermatitis Medicamentosa [description not available]	0	2.06	1	0
Arthritides, Bacterial [description not available]	0	2.07	1	0
Infections, Prosthesis-Related [description not available]	0	2.07	1	0
Blood Clot [description not available]	0	2.07	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	2.07	1	0
Spinal Diseases Diseases involving the SPINE.	0	2.08	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	0	2.08	1	0
Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER.	0	2.08	1	0
Critical Illness A disease or state in which death is possible or imminent.	0	2.94	1	0
Experimental Pneumococcal Meningitis [description not available]	0	2.94	1	0
Bacterial Meningitides [description not available]	0	2.94	1	0
Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)	0	2.94	1	0
Meningitis, Bacterial Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.	0	2.94	1	0

telavancin

Description

Cross-References

Synonyms (36)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Roles (2)

Drug Classes (1)

Bioassays (850)

Research

Studies (243)

Market Indicators

Research Demand Index: 48.26

Study Types

Clinical Trials (17)

Trial Overview

Trial Outcomes

Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population

Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With Bacteremia, Metastatic Complications, or Positive Culture at the Test of Cure Evaluation

Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population

Clinical Response

Clinical Response

Clinical Response

Clinical Response

Patient Clinical Response to Telavancin

Investigator Clinical Response (Success or Failure) at EOT in the Microbiological All-treated (mAT) Population

Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)

Number of Participants With an Investigator Clinical Outcome of Cure at TOC in the Microbiological All-treated (mAT) Population

Number of Participants With the Development of a New Metastatic Foci of S. Aureus Infection at Test of Cure (TOC) in the Microbiological All-treated (mAT) Populations

AUC0-24 of Telavancin

AUC24-48 of Telavancin

CLobs of Telavancin

Cmax of Telavancin

t1/2 of Telavancin

Vss of Telavancin

Related Drugs (661)

Related Conditions (98)